Ronald N. Jones

发表

Interpretive Criteria andQuality Control Limits forCeftibuten DiskSusceptibility Tests

Arthur L. Barry, Ronald N. Jones, 1990 .

Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009).

Ronald N. Jones, M. Castanheira, M. Pfaller, 2010, Diagnostic microbiology and infectious disease.

In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation.

Ronald N. Jones, Gary J. Moet, T. Fritsche, 2008, Diagnostic microbiology and infectious disease.

Initial results from a longitudinal international surveillance programme for anidulafungin (2003).

Ronald N. Jones, S. Messer, T. Fritsche, 2004, The Journal of antimicrobial chemotherapy.

Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014

Ronald N. Jones, M. Castanheira, H. Sader, 2017, Antimicrobial Agents and Chemotherapy.

Contemporary Diversity of β-Lactamases among Enterobacteriaceae in the Nine U.S. Census Regions and Ceftazidime-Avibactam Activity Tested against Isolates Producing the Most Prevalent β-Lactamase Groups

Ronald N. Jones, M. Castanheira, K. Krause, 2013, Antimicrobial Agents and Chemotherapy.

Activity of Ceftaroline against Recent Emerging Serotypes of Streptococcus pneumoniae in the United States

Ronald N. Jones, Michael R. Jacobs, Helio S. Sader, 2010, Antimicrobial Agents and Chemotherapy.

Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09).

Ronald N. Jones, A. Gales, H. Sader, 2011, The Journal of antimicrobial chemotherapy.

Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010).

Ronald N. Jones, M. Castanheira, A. Gales, 2012, Diagnostic microbiology and infectious disease.

10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America.

Ronald N. Jones, R. Bonomo, D. Gilbert, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Oral β-lactams applied to uncomplicated infections of skin and skin structures

Ronald N. Jones, M. Jacobs, P. Giordano, 2007 .

Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007).

Ronald N. Jones, Mariana Castanheira, M. Castanheira, 2008, Microbial drug resistance.

Interpretive categorical accuracy of fluoroquinolone reference broth microdilution MIC results when testing Streptococcus pneumoniae: selection of a surrogate testing agent.

Ronald N. Jones, L. Koeth, H. Sader, 2008, Diagnostic microbiology and infectious disease.

Early Dissemination of NDM-1- and OXA-181-Producing Enterobacteriaceae in Indian Hospitals: Report from the SENTRY Antimicrobial Surveillance Program, 2006-2007

Ronald N. Jones, M. Castanheira, D. Mathai, 2010, Antimicrobial Agents and Chemotherapy.

Multicenter Studies of Tigecycline Disk Diffusion Susceptibility Results for Acinetobacter spp

Ronald N. Jones, M. Ferraro, L. Reller, 2006, Journal of Clinical Microbiology.

In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria.

Ronald N. Jones, P. Rhomberg, H. Sader, 2016, The Journal of antimicrobial chemotherapy.

Genotypic characterization of carbapenem-nonsusceptible Acinetobacter spp. isolated in Latin America.

Ronald N. Jones, M. Pfaller, A. Gales, 2004, Microbial drug resistance.

Dissemination and diversity of metallo-beta-lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program.

Ronald N. Jones, M. Castanheira, M. Toleman, 2005, International journal of antimicrobial agents.

Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae

Ronald N. Jones, M. Castanheira, P. Rhomberg, 2016, Antimicrobial Agents and Chemotherapy.

Evolution of Ceftaroline-Resistant Mrsa in a Child with Cystic Fibrosis Following Repeated Antibiotic Exposure

Ronald N. Jones, D. Farrell, J. Le, 2016, The Pediatric infectious disease journal.

Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program

Ronald N. Jones, M. Castanheira, R. Cantón, 2019, Open forum infectious diseases.

Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).

Ronald N. Jones, D. Biedenbach, 2009, Diagnostic microbiology and infectious disease.

Characterization of Baseline Methicillin-Resistant Staphylococcus aureus Isolates Recovered from Phase IV Clinical Trial for Linezolid

Ronald N. Jones, B. Diep, H. Chambers, 2009, Journal of Clinical Microbiology.

Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates.

Ronald N. Jones, M. Castanheira, P. Rhomberg, 2010, International journal of antimicrobial agents.

Microbiology of newer fluoroquinolones: focus on respiratory pathogens.

Ronald N. Jones, 2002, Diagnostic microbiology and infectious disease.

Activity of Fusidic Acid Tested against Staphylococci Isolated from Patients in U.S. Medical Centers in 2014

Ronald N. Jones, M. Castanheira, D. Farrell, 2016, Antimicrobial Agents and Chemotherapy.

In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United States.

Ronald N. Jones, M. Castanheira, H. Sader, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada.

Ronald N. Jones, M. Castanheira, M. Pfaller, 2010, International journal of antimicrobial agents.

Fusidic Acid Resistance Rates and Prevalence of Resistance Mechanisms among Staphylococcus spp. Isolated in North America and Australia, 2007-2008

Ronald N. Jones, M. Castanheira, J. Turnidge, 2010, Antimicrobial Agents and Chemotherapy.

Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008).

Ronald N. Jones, M. Castanheira, D. Farrell, 2010, The Journal of antimicrobial chemotherapy.

Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102).

Ronald N. Jones, P. Rhomberg, R. Mendes, 2010, Diagnostic microbiology and infectious disease.

Binaphthyl-based dicationic peptoids with therapeutic potential.

Ronald N. Jones, Michael H. Miller, J. Deadman, 2010, Angewandte Chemie.

Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002).

Ronald N. Jones, J. Turnidge, S. Kamihira, 2005, Diagnostic microbiology and infectious disease.

Case Report of Aurantimonas altamirensis Bloodstream Infection

Ronald N. Jones, Gerald A. Denys, T. Fritsche, 2008, Journal of Clinical Microbiology.

Determination of Disk Diffusion and MIC Quality Control Ranges for GSK1322322, a Novel Peptide Deformylase Inhibitor

Ronald N. Jones, Helio S. Sader, L. Miller, 2011, Journal of Clinical Microbiology.

Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents.

Ronald N. Jones, T. Fritsche, H. Sader, 2005, International journal of antimicrobial agents.

In Vitro Activity of a New Oral Glucan Synthase Inhibitor (MK-3118) Tested against Aspergillus spp. by CLSI and EUCAST Broth Microdilution Methods

Ronald N. Jones, Mariana Castanheira, M. Castanheira, 2012, Antimicrobial Agents and Chemotherapy.

Activity of Retapamulin (SB-275833), a Novel Pleuromutilin, against Selected Resistant Gram-Positive Cocci

Ronald N. Jones, Helio S. Sader, T. Fritsche, 2006, Antimicrobial Agents and Chemotherapy.

WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015

Ronald N. Jones, Helio S. Sader, Mariana Castanheira, 2017, Antimicrobial Agents and Chemotherapy.

Antimicrobial Activity of the Investigational Pleuromutilin Compound BC-3781 Tested against Gram-Positive Organisms Commonly Associated with Acute Bacterial Skin and Skin Structure Infections

Ronald N. Jones, Helio S. Sader, Douglas J. Biedenbach, 2012, Antimicrobial Agents and Chemotherapy.

Changes in the Frequencies of β-Lactamase Genes among Enterobacteriaceae Isolates in U.S. Hospitals, 2012 to 2014: Activity of Ceftazidime-Avibactam Tested against β-Lactamase-Producing Isolates

Ronald N. Jones, Helio S. Sader, Mariana Castanheira, 2016, Antimicrobial Agents and Chemotherapy.

Worldwide Antimicrobial Susceptibility Patterns and Pharmacodynamic Comparisons of Gatifloxacin and Levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team

Ronald N. Jones, S. Bhavnani, P. Ambrose, 2003, Antimicrobial Agents and Chemotherapy.

Pharmacodynamics in the Evaluation of Drug Regimens

Ronald N. Jones, S. Bhavnani, P. Ambrose, 2002, The Annals of pharmacotherapy.

Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime.

Ronald N. Jones, M. Garvey, R. Owens, 2002, The Journal of antimicrobial chemotherapy.

Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae.

Ronald N. Jones, L. Mandell, D. Andes, 2002, Diagnostic microbiology and infectious disease.

International Surveillance of Candida spp. and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2003)

Ronald N. Jones, S. Messer, T. Fritsche, 2006, Journal of Clinical Microbiology.

Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13).

Ronald N. Jones, D. Farrell, H. Sader, 2015, The Journal of antimicrobial chemotherapy.

Prevalence of β-Lactamase-Encoding Genes among Enterobacteriaceae Bacteremia Isolates Collected in 26 U.S. Hospitals: Report from the SENTRY Antimicrobial Surveillance Program (2010)

Ronald N. Jones, M. Castanheira, R. Mendes, 2013, Antimicrobial Agents and Chemotherapy.

Prevalence and Significance of a Negative Extended-Spectrum β-Lactamase (ESBL) Confirmation Test Result after a Positive ESBL Screening Test Result for Isolates of Escherichia coli and Klebsiella pneumoniae: Results from the SENTRY Asia-Pacific Surveillance Program

Ronald N. Jones, J. Turnidge, M. Barton, 2007, Journal of Clinical Microbiology.

Susceptibility testing accuracy of a CTX-M-type extended-spectrum beta-lactamase organism-producing population of Enterobacteriaceae: intermethod analysis for 9 beta-lactams.

Ronald N. Jones, H. Sader, Yunsong Yu, 2005, Diagnostic microbiology and infectious disease.

Antimicrobial susceptibility study Susceptibility testing accuracy of a CTX-M-type extended-spectrum h-lactamase organism-producing population of Enterobacteriaceae: intermethod analysis for 9 h-lactams

Ronald N. Jones, H. Sader, Yunsong Yu, 2005 .

Reevaluation of the cefepime minimal inhibitory concentrations and disk diffusion test zone diameter relationship for a worldwide collection of Enterobacteriaceae enriched for extended-spectrum beta-lactamase-producing organisms.

Ronald N. Jones, H. Sader, L. Deshpande, 2005, Diagnostic microbiology and infectious disease.

Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases.

Ronald N. Jones, W. Craig, M. Dudley, 2005, Diagnostic microbiology and infectious disease.

Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003).

Ronald N. Jones, T. Fritsche, H. Sader, 2004, Diagnostic microbiology and infectious disease.

Molecular and Biochemical Characterization of OXA-45, an Extended-Spectrum Class 2d′ β-Lactamase in Pseudomonas aeruginosa

Ronald N. Jones, M. Toleman, T. Walsh, 2003, Antimicrobial Agents and Chemotherapy.

Dissemination of a pSCFS3-Like cfr-Carrying Plasmid in Staphylococcus aureus and Staphylococcus epidermidis Clinical Isolates Recovered from Hospitals in Ohio

Ronald N. Jones, J. Quinn, M. Huband, 2013, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).

Ronald N. Jones, T. Fritsche, H. Sader, 2008, Diagnostic microbiology and infectious disease.

Identification of Uncommon Clinically Important Yeasts and Moulds by the Bruker Biotyper Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) System in a Global Antifungal Surveillance Program

Ronald N. Jones, M. Castanheira, M. Pfaller, 2015 .

Isavuconazole and Nine Comparator Antifungal Susceptibility Profiles for Common and Uncommon Candida Species Collected in 2012: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values

Ronald N. Jones, M. Castanheira, P. Rhomberg, 2014, Mycopathologia.

Significance of Molecular Identification and Antifungal Susceptibility of Clinically Significant Yeasts and Moulds in a Global Antifungal Surveillance Programme

Ronald N. Jones, M. Castanheira, M. Pfaller, 2012, Mycopathologia.

Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003).

Ronald N. Jones, T. Fritsche, M. Stilwell, 2006, Diagnostic microbiology and infectious disease.

Decreased Ceftriaxone Susceptibility in Emerging (35B and 6C) and Persisting (19A) Streptococcus pneumoniae Serotypes in the United States, 2011-2012: Ceftaroline Remains Active In Vitro among β-Lactam Agents

Ronald N. Jones, D. Farrell, H. Sader, 2014, Antimicrobial Agents and Chemotherapy.

Multicenter Evaluation of the Antimicrobial Activity for Six Broad-Spectrum β-Lactams in Venezuela Using the Etest Method

Ronald N. Jones, M. Pfaller, G. Doern, 1998 .

Accuracy of Three Automated Systems (MicroScan WalkAway, VITEK, and VITEK 2) for Susceptibility Testing of Pseudomonas aeruginosa against Five Broad-Spectrum Beta-Lactam Agents

Ronald N. Jones, T. Fritsche, H. Sader, 2006, Journal of Clinical Microbiology.

Methods for Improved Detection of Oxacillin Resistance in Coagulase-Negative Staphylococci: Results of a Multicenter Study

Ronald N. Jones, B. Zimmer, S. McAllister, 1999, Journal of Clinical Microbiology.

Evaluation of Reference Dilution Test Methods for Antimicrobial Susceptibility Testing of Pseudomonas aeruginosa Strains Isolated from Patients with Cystic Fibrosis

Ronald N. Jones, L. Saiman, J. Burns, 1999, Journal of Clinical Microbiology.

Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).

Ronald N. Jones, H. Sader, 2009, Diagnostic microbiology and infectious disease.

Molecular Characterization of a β-Lactamase Gene, blaGIM-1, Encoding a New Subclass of Metallo-β-Lactamase

Ronald N. Jones, M. Castanheira, F. Schmidt, 2004, Antimicrobial Agents and Chemotherapy.

Activity of Debio1452, a FabI Inhibitor with Potent Activity against Staphylococcus aureus and Coagulase-Negative Staphylococcus spp., Including Multidrug-Resistant Strains

Ronald N. Jones, N. Kaplan, P. Rhomberg, 2015, Antimicrobial Agents and Chemotherapy.

Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy.

Ronald N. Jones, G. Fadda, D. Farrell, 2010, The Journal of antimicrobial chemotherapy.

Antimicrobial susceptibility patterns of beta-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997-2000).

Ronald N. Jones, P. Rhomberg, A. Mutnick, 2002, Diagnostic microbiology and infectious disease.

Oxazolidinone antibiotics

Ronald N. Jones, D. Diekema, 2001, The Lancet.

Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa

Ronald N. Jones, M. Huband, P. Rhomberg, 2018, Journal of Clinical Microbiology.

and Interpretive Criteria of Candida by Using CLSI Methods and Caspofungin among 4 , 290 Clinical Isolates To Predict Susceptibility and Resistance to Use of Anidulafungin as a Surrogate Marker

Ronald N. Jones, M. Castanheira, M. Pfaller, 2014 .

Use of Anidulafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 4,290 Clinical Isolates of Candida by Using CLSI Methods and Interpretive Criteria

Ronald N. Jones, M. Castanheira, M. Pfaller, 2014, Journal of Clinical Microbiology.

Use of Micafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 3,764 Clinical Isolates of Candida by Use of CLSI Methods and Interpretive Criteria

Ronald N. Jones, M. Castanheira, M. Pfaller, 2013, Journal of Clinical Microbiology.

Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.

Ronald N. Jones, J. Bertino, J. Segreti, 2012, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Triazole and Echinocandin MIC Distributions with Epidemiological Cutoff Values for Differentiation of Wild-Type Strains from Non-Wild-Type Strains of Six Uncommon Species of Candida

Ronald N. Jones, M. Castanheira, M. Pfaller, 2011, Journal of Clinical Microbiology.

Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.

Ronald N. Jones, M. Castanheira, M. Pfaller, 2011, Diagnostic microbiology and infectious disease.

Definitions and Epidemiology of Candida Species not Susceptible to Echinocandins

Ronald N. Jones, M. Castanheira, M. Pfaller, 2011 .

Development of a Disk Diffusion Method for Testing Moraxella catarrhalis Susceptibility Using Clinical and Laboratory Standards Institute Methods: a SENTRY Antimicrobial Surveillance Program Report

Ronald N. Jones, J. Turnidge, J. Bell, 2009, Journal of Clinical Microbiology.

Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia

Ronald N. Jones, R. Wunderink, J. Rello, 2017, Antimicrobial Agents and Chemotherapy.

Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa.

Ronald N. Jones, P. Savage, M. Rybak, 2007, The Journal of antimicrobial chemotherapy.

Genetic characterization of a novel metallo-beta-lactamase gene, blaIMP-13, harboured by a novel Tn5051-type transposon disseminating carbapenemase genes in Europe: report from the SENTRY worldwide antimicrobial surveillance programme.

Ronald N. Jones, M. Toleman, T. Walsh, 2003, The Journal of antimicrobial chemotherapy.

Emergence of an IMP-like metallo-enzyme in an Acinetobacter baumannii clinical strain from a Brazilian teaching hospital.

Ronald N. Jones, A. Gales, H. Sader, 2003, Diagnostic microbiology and infectious disease.

Antimicrobial Activity of Prulifloxacin Tested against a Worldwide Collection of Gastroenteritis-Producing Pathogens, Including Those Causing Traveler's Diarrhea

Ronald N. Jones, T. Fritsche, D. Biedenbach, 2008, Antimicrobial Agents and Chemotherapy.

Antimicrobial Activity of DC-159a, a New Fluoroquinolone, against 1,149 Recently Collected Clinical Isolates

Ronald N. Jones, T. Fritsche, H. Sader, 2008, Antimicrobial Agents and Chemotherapy.

In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).

Ronald N. Jones, M. Castanheira, D. Farrell, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gram-negative bacilli.

Ronald N. Jones, H. Sader, Helio S Sader, 2003, Diagnostic microbiology and infectious disease.

In Vitro Activity of Ceftaroline Alone and in Combination against Clinical Isolates of Resistant Gram-Negative Pathogens, Including β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa

Ronald N. Jones, M. Rybak, Steven N. Leonard, 2009, Antimicrobial Agents and Chemotherapy.

Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.

Ronald N. Jones, T. Fritsche, H. Sader, 2005, Diagnostic microbiology and infectious disease.

Educational antimicrobial susceptibility testing as a critical component of microbiology laboratory proficiency programs: American Proficiency Institute results for 2007-2011.

Ronald N. Jones, P. Rhomberg, H. Sader, 2013, Diagnostic microbiology and infectious disease.

Update on Linezolid In Vitro Activity through the Zyvox Annual Appraisal of Potency and Spectrum Program, 2013

Ronald N. Jones, R. Mendes, R. Flamm, 2015, Antimicrobial Agents and Chemotherapy.

Program 2011 United States: LEADER Surveillance Linezolid Surveillance Results for the

Ronald N. Jones, R. Mendes, R. Flamm, 2014 .

Summary of Linezolid Activity and Resistance Mechanisms Detected during the 2012 LEADER Surveillance Program for the United States

Ronald N. Jones, R. Mendes, R. Flamm, 2013, Antimicrobial Agents and Chemotherapy.

Expansion of Clonal Complex 258 KPC-2-Producing Klebsiella pneumoniae in Latin American Hospitals: Report of the SENTRY Antimicrobial Surveillance Program

Ronald N. Jones, M. Castanheira, L. Deshpande, 2012, Antimicrobial Agents and Chemotherapy.

Linezolid Surveillance Results for the United States: LEADER Surveillance Program 2011

Ronald N. Jones, H. Sader, R. Mendes, 2012, Antimicrobial Agents and Chemotherapy.

In Vitro Activity and Single-Step Mutational Analysis of Rifamycin SV Tested against Enteropathogens Associated with Traveler's Diarrhea and Clostridium difficile

Ronald N. Jones, D. Farrell, G. Celasco, 2010, Antimicrobial Agents and Chemotherapy.

Carbapenem Resistance among Pseudomonas aeruginosa Strains from India: Evidence for Nationwide Endemicity of Multiple Metallo-β-Lactamase Clones (VIM-2, -5, -6, and -11 and the Newly Characterized VIM-18)

Ronald N. Jones, M. Castanheira, J. Turnidge, 2008, Antimicrobial Agents and Chemotherapy.

Characterization of an Integron Carrying blaIMP-1 and a New Aminoglycoside Resistance Gene, aac(6′)-31, and Its Dissemination among Genetically Unrelated Clinical Isolates in a Brazilian Hospital

Ronald N. Jones, M. Castanheira, M. Toleman, 2007, Antimicrobial Agents and Chemotherapy.

Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006).

Ronald N. Jones, P. Rhomberg, J. T. Kirby, 2007, Diagnostic microbiology and infectious disease.

Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004).

Ronald N. Jones, P. Rhomberg, T. Fritsche, 2006, Diagnostic microbiology and infectious disease.

Molecular epidemiology of selected multidrug-resistant bacteria: a global report from the SENTRY Antimicrobial Surveillance Program.

Ronald N. Jones, T. Fritsche, L. Deshpande, 2004, Diagnostic microbiology and infectious disease.

Antimicrobial Susceptibility and Epidemiology of a Worldwide Collection of Chryseobacterium spp.: Report from the SENTRY Antimicrobial Surveillance Program (1997-2001)

Ronald N. Jones, T. Walsh, J. T. Kirby, 2004, Journal of Clinical Microbiology.

Molecular Epidemiology of Macrolide Resistance in Neonatal Bloodstream Isolates of Group B Streptococci

Ronald N. Jones, P. Rhomberg, M. Pfaller, 2003, Journal of Clinical Microbiology.

Typing and molecular characterization of Streptococcus pneumoniae with reduced susceptibility to cefotaxime isolated in Latin America.

Ronald N. Jones, M. Castanheira, M. Brandileone, 2003, Microbial drug resistance.

In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum.

Ronald N. Jones, P. Rhomberg, 2002, Diagnostic microbiology and infectious disease.

Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance program.

Ronald N. Jones, D. Biedenbach, 2003, Diagnostic microbiology and infectious disease.

Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000-2001): report from the SENTRY Antimicrobial Surveillance Program.

Ronald N. Jones, D. Biedenbach, M. Beach, 2003, Diagnostic microbiology and infectious disease.

Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor.

Ronald N. Jones, P. Rhomberg, 2003, The Journal of antimicrobial chemotherapy.

Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000).

Ronald N. Jones, K. A. Gordon, 2003, Diagnostic microbiology and infectious disease.

Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001).

Ronald N. Jones, D. Biedenbach, 2003, Diagnostic microbiology and infectious disease.

A comparison of the antimicrobial activity of meropenem and selected broad-spectrum antimicrobials tested against multi-drug resistant Gram-negative bacilli including bacteraemic Salmonella spp.: initial studies for the MYSTIC programme in India.

Ronald N. Jones, D. Mathai, P. Rhomberg, 2002, International journal of antimicrobial agents.

Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories.

Ronald N. Jones, D. Mathai, P. Rhomberg, 2002, Diagnostic microbiology and infectious disease.

Antimicrobial activity of broad-spectrum agents tested against Gram-negative bacilli resistant to ceftazidime: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).

Ronald N. Jones, D. Varnam, 2002, Diagnostic microbiology and infectious disease.

Impact of Modified Nonmeningeal Streptococcus pneumoniae Interpretive Criteria (NCCLS M100-S12) on the Susceptibility Patterns of Five Parenteral Cephalosporins: Report from the SENTRY Antimicrobial Surveillance Program (1997 to 2001)

Ronald N. Jones, A. Mutnick, D. Varnam, 2002, Journal of Clinical Microbiology.

Activity of Plazomicin Tested against Enterobacterales Isolates Collected from U.S. Hospitals in 2016–2017: Effect of Different Breakpoint Criteria on Susceptibility Rates among Aminoglycosides

Ronald N. Jones, M. Castanheira, H. Sader, 2020, Antimicrobial Agents and Chemotherapy.

Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming Patients

Ronald N. Jones, D. Andes, J. Bradley, 2020, Open forum infectious diseases.

Antimicrobial Susceptibility of Streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific Region: Results From 20 Years of the SENTRY Antimicrobial Surveillance Program (1997–2016)

Ronald N. Jones, J. Le, H. Sader, 2019, Open forum infectious diseases.

Application of Next-Generation Sequencing for Characterization of Surveillance and Clinical Trial Isolates: Analysis of the Distribution of β-lactamase Resistance Genes and Lineage Background in the United States

Ronald N. Jones, M. Castanheira, V. Cattoir, 2019, Open forum infectious diseases.

Multicenter Investigation of Gepotidacin (GSK2140944) Agar Dilution Quality Control Determinations for Neisseria gonorrhoeae ATCC 49226

Ronald N. Jones, R. Flamm, Kelley A Fedler, 2016, Antimicrobial Agents and Chemotherapy.

Haemophilus influenzae and Moraxella catarrhalis from Patients with Community-Acquired Respiratory Tract Infections: Antimicrobial Susceptibility Patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)

Ronald N. Jones, M. Pfaller, G. Doern, 1999, Antimicrobial Agents and Chemotherapy.

Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study.

Ronald N. Jones, D. Farrell, H. Sader, 2011, The Journal of antimicrobial chemotherapy.

Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001).

Ronald N. Jones, P. Rhomberg, A. Mutnick, 2004, The Journal of antimicrobial chemotherapy.

Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study.

Ronald N. Jones, H. Sader, R. Mendes, 2010, The Journal of antimicrobial chemotherapy.

Evolution of an integron carrying blaVIM-2 in Eastern Europe: report from the SENTRY Antimicrobial Surveillance Program.

Ronald N. Jones, P. Bennett, M. Toleman, 2003, The Journal of antimicrobial chemotherapy.

Antimicrobial susceptibility patterns of unusual nonfermentative gram-negative bacilli isolated from Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2002).

Ronald N. Jones, S. S. Andrade, A. Gales, 2005, Memorias do Instituto Oswaldo Cruz.

Ceftaroline Activity Tested against Bacterial Isolates Causing Community-Acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients from United States Hospitals: 2012-2014.

Ronald N. Jones, M. Castanheira, M. Pfaller, 2017, The Pediatric infectious disease journal.

In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance Program

Ronald N. Jones, R. Mendes, M. Dunne, 2015, Antimicrobial Agents and Chemotherapy.

ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries

Ronald N. Jones, D. Farrell, H. Sader, 2012, Journal of chemotherapy.

Molecular Analysis of Tn 1546 in Enterococcus faecium Isolated from Animals and Humans

Ronald N. Jones, F. Aarestrup, L. Dons, 1998 .

Molecular Analysis of Tn1546 inEnterococcus faecium Isolated from Animals and Humans

Ronald N. Jones, F. Aarestrup, L. Dons, 1998, Journal of Clinical Microbiology.

First Descriptions of blaKPC in Raoultella spp. (R. planticola and R. ornithinolytica): Report from the SENTRY Antimicrobial Surveillance Program

Ronald N. Jones, M. Weinstein, M. Castanheira, 2009, Journal of Clinical Microbiology.

Linezolid Resistance since 2001: SENTRY Antimicrobial Surveillance Program

Ronald N. Jones, A. Mutnick, V. Enne, 2003, The Annals of pharmacotherapy.

Application of an In Vitro Infection Model and Simulation for Reevaluation of Fluoroquinolone Breakpoints for Salmonella enterica Serotype Typhi

Ronald N. Jones, Patrick F. Smith, S. Bhavnani, 2005, Antimicrobial Agents and Chemotherapy.

Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers.

Ronald N. Jones, H. Sader, D. Biedenbach, 2002, Diagnostic microbiology and infectious disease.

Development of anidulafungin for disk diffusion susceptibility testing against Candida spp.

Ronald N. Jones, S. Messer, J. T. Kirby, 2007, Diagnostic microbiology and infectious disease.

A multicenter evaluation of linezolid antimicrobial activity in North America.

Ronald N. Jones, D. Biedenbach, C. Ballow, 2002, Diagnostic microbiology and infectious disease.

Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000).

Ronald N. Jones, D. Hoban, A. Mutnick, 2003, Diagnostic microbiology and infectious disease.

Arbekacin Activity against Contemporary Clinical Bacteria Isolated from Patients Hospitalized with Pneumonia

Ronald N. Jones, P. Rhomberg, D. Farrell, 2015, Antimicrobial Agents and Chemotherapy.

Ceftobiprole Activity against over 60,000 Clinical Bacterial Pathogens Isolated in Europe, Turkey, and Israel from 2005 to 2010

Ronald N. Jones, D. Farrell, H. Sader, 2014, Antimicrobial Agents and Chemotherapy.

Antimicrobial Activity of the Pleuromutilin Antibiotic BC-3781 against Bacterial Pathogens Isolated in the SENTRY Antimicrobial Surveillance Program in 2010

Ronald N. Jones, S. Paukner, H. Sader, 2013, Antimicrobial Agents and Chemotherapy.

Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia.

Ronald N. Jones, M. Pfaller, H. Sader, 2010, The Journal of antimicrobial chemotherapy.

bla VIM-7, an Evolutionarily Distinct Metallo-β-Lactamase Gene in a Pseudomonas aeruginosa Isolate from the United States

Ronald N. Jones, M. Toleman, T. Walsh, 2004, Antimicrobial Agents and Chemotherapy.

Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.

Ronald N. Jones, T. Fritsche, H. Sader, 2007, Diagnostic microbiology and infectious disease.

Macrolide and tetracycline resistance among Moraxella catarrhalis isolates from 2009 to 2011.

Ronald N. Jones, D. Farrell, H. Sader, 2012, Diagnostic microbiology and infectious disease.

In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America.

Ronald N. Jones, S. S. Andrade, A. Gales, 2005, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?

Ronald N. Jones, T. Fritsche, H. Sader, 2005, Diagnostic microbiology and infectious disease.

Critical assessment of the newer non-quinolone oral antimicrobial agents

Ronald N. Jones, 1989 .

MINIREVIEW Antimicrobial Susceptibility Testing of Haemophilus influenzae, Branhamella catarrhalis, and Neisseria gonorrhoeae

Ronald N. Jones, Gary V. DOERNl, 2022 .

In vitro evaluation of cefepime and other broad-spectrum β-lactams for isolates in Malaysia and Singapore medical centers

Ronald N. Jones, D. Biedenbach, M. Lewis, 1999 .

Recent trends in the college of American pathologists proficiency results for antimicrobial susceptibility testing: Preparing for CLIA '88

Ronald N. Jones, 1992 .

Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists Microbiology Surveys Program (2001-2003).

Ronald N. Jones, M. Pfaller, 2006, Archives of pathology & laboratory medicine.

Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997-2001).

Ronald N. Jones, S. S. Andrade, A. Gales, 2003, The Journal of antimicrobial chemotherapy.

Comparison of the probability of target attainment between ceftriaxone and cefepime in the cerebrospinal fluid and serum against Streptococcus pneumoniae.

Ronald N. Jones, M. Kinzig, G. Drusano, 2007, Diagnostic microbiology and infectious disease.

Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004).

Ronald N. Jones, G. Fadda, G. Nicoletti, 2006, Diagnostic microbiology and infectious disease.

Comparative activity of oral and parenteral cephalosporins tested against multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1997-2003).

Ronald N. Jones, T. Fritsche, S. Pottumarthy, 2005, Diagnostic microbiology and infectious disease.

In Vitro Activities of the Novel Cephalosporin LB 11058 against Multidrug-Resistant Staphylococci and Streptococci

Ronald N. Jones, H. Sader, David M. Johnson, 2004, Antimicrobial Agents and Chemotherapy.

Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002).

Ronald N. Jones, T. Fritsche, A. Mutnick, 2003, Diagnostic microbiology and infectious disease.

Fluoroquinolones for the treatment of outpatient community-acquired pneumonia.

Ronald N. Jones, L. Mandell, 2002, Diagnostic microbiology and infectious disease.

Rapid expansion of KPC-2-producing Klebsiella pneumoniae isolates in two Texas hospitals due to clonal spread of ST258 and ST307 lineages.

Ronald N. Jones, M. Castanheira, A. Wanger, 2013, Microbial drug resistance.

Occurrence of plasmidic AmpC type beta-lactamase-mediated resistance in Escherichia coli: report from the SENTRY Antimicrobial Surveillance Program (North America, 2004).

Ronald N. Jones, T. Fritsche, H. Sader, 2006, International journal of antimicrobial agents.

Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine.

Ronald N. Jones, R. Mera, T. Fritsche, 2008, Microbial drug resistance.

Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States.

Ronald N. Jones, S. Bhavnani, P. Ambrose, 2005, Diagnostic microbiology and infectious disease.

Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).

Ronald N. Jones, T. Fritsche, H. Sader, 2005, Diagnostic microbiology and infectious disease.

Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres.

Ronald N. Jones, P. Rhomberg, H. Sader, 2004, International journal of antimicrobial agents.

Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine.

Ronald N. Jones, M. Jacobs, R. Mendes, 2014, Diagnostic microbiology and infectious disease.

Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011.

Ronald N. Jones, H. Sader, R. Flamm, 2014, Diagnostic microbiology and infectious disease.

Variation in Potency and Spectrum of Tigecycline Activity against Bacterial Strains from U.S. Medical Centers since Its Approval for Clinical Use (2006 to 2012)

Ronald N. Jones, D. Farrell, H. Sader, 2014, Antimicrobial Agents and Chemotherapy.

Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99).

Ronald N. Jones, J. Turnidge, M. Pfaller, 2002, Diagnostic microbiology and infectious disease.

Evaluation of Vancomycin and Daptomycin Potency Trends (MIC Creep) against Methicillin-Resistant Staphylococcus aureus Isolates Collected in Nine U.S. Medical Centers from 2002 to 2006

Ronald N. Jones, D. Snydman, P. Fey, 2009, Antimicrobial Agents and Chemotherapy.

Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).

Ronald N. Jones, M. Pfaller, J. T. Kirby, 2002, Diagnostic microbiology and infectious disease.

Short communication Characterization of extended spectrum -lactamase-producing Klebsiella pneumoniae from Beijing, China

Ronald N. Jones, P. Winokur, D. Shen, 2001 .

Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016

Ronald N. Jones, M. Castanheira, J. Turnidge, 2019, Open forum infectious diseases.

Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST).

Ronald N. Jones, M. Castanheira, M. Pfaller, 2013, The Journal of antimicrobial chemotherapy.

Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance.

Ronald N. Jones, M. Weinstein, K. Klugman, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Multicenter evaluation of antimicrobial resistance to six broad-spectrum β-lactams in Colombia: comparison of data from 1997 and 1998 using the Etest method☆

Ronald N. Jones, M. Pfaller, G. Doern, 1999 .

Multicenter evaluation of the antimicrobial activity for six broad-spectrum β-lactams in Venezuela: comparison of data from 1997 and 1998 using the Etest method

Ronald N. Jones, M. Pfaller, G. Doern, 1999 .

Evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan

Ronald N. Jones, K. Yamaguchi, D. Mathai, 1999 .

Development, characterization, and initial evaluations of S1 a new chromogenic cephalosporin for β-lactamase delection

Ronald N. Jones, D. Biedenbach, A. Yen, 1995 .

Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).

Ronald N. Jones, M. Toleman, T. Walsh, 2006, Diagnostic microbiology and infectious disease.

Ceftaroline Activity Against Multidrug-Resistant Streptococcus pneumoniae from U.S. Medical Centers (2014) and Molecular Characterization of a Single Ceftaroline Nonsusceptible Isolate.

Ronald N. Jones, M. Pfaller, H. Sader, 2017, Microbial drug resistance.

Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline.

Ronald N. Jones, A. Tsakris, H. Sader, 2012, The Journal of antimicrobial chemotherapy.

Genotypic and phenotypic characterization of methicillin-resistant Staphylococcus aureus strains recovered from a Phase IV clinical trial for linezolid versus vancomycin for the treatment of nosocomial pneumonia

Ronald N. Jones, D. Farrell, B. Shopsin, 2012 .

Haemophilus influenzae in respiratory tract infections in community-based clinical practice: therapy with gatifloxacin.

Ronald N. Jones, W. Wilson, S. Nicholson, 2002, Diagnostic microbiology and infectious disease.

Antimicrobial Activity and Spectrum Investigation of Eight Broad-Spectrum β-Lactam Drugs: A 1997 Surveillance Trial in 102 Medical Centers in the United States

Ronald N. Jones, M. Pfaller, G. Doern, 1998 .

Contemporary Assessment of Antimicrobial Susceptibility Testing Methods for Polymyxin B and Colistin: Review of Available Interpretative Criteria and Quality Control Guidelines

Ronald N. Jones, A. Gales, A. O. Reis, 2001, Journal of Clinical Microbiology.

Escherichia coli resistance to quinolones at a comprehensive cancer center.

Ronald N. Jones, P. Rhomberg, K. Rolston, 2010, Diagnostic microbiology and infectious disease.

LEADER Program Results for 2009: an Activity and Spectrum Analysis of Linezolid Using 6,414 Clinical Isolates from 56 Medical Centers in the United States

Ronald N. Jones, D. Farrell, H. Sader, 2011, Antimicrobial Agents and Chemotherapy.

Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.

Ronald N. Jones, J. Turnidge, I. Kobayashi, 2009, Diagnostic microbiology and infectious disease.

Antimicrobial activity of cefditoren tested against contemporary (2004-2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States.

Ronald N. Jones, T. Fritsche, D. Biedenbach, 2008, Diagnostic microbiology and infectious disease.

Symposium section Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae

Ronald N. Jones, T. Fritsche, H. Sader, 2007 .

Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.

Ronald N. Jones, T. Fritsche, H. Sader, 2005, Diagnostic microbiology and infectious disease.

Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999-2002).

Ronald N. Jones, T. Fritsche, H. Sader, 2004, Diagnostic microbiology and infectious disease.

Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program.

Ronald N. Jones, D. Biedenbach, K. A. Gordon, 2003, Diagnostic microbiology and infectious disease.

Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.

Ronald N. Jones, T. Fritsche, H. Sader, 2007, Diagnostic microbiology and infectious disease.

Characterization of Vancomycin-Heteroresistant Staphylococcus aureus from the Metropolitan Area of Detroit, Michigan, over a 22-Year Period (1986 to 2007)

Ronald N. Jones, M. Rybak, Steven N. Leonard, 2008, Journal of Clinical Microbiology.

Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers.

Ronald N. Jones, H. Sader, R. Mendes, 2008, Diagnostic microbiology and infectious disease.

Antimicrobial Activities of Ceftaroline and ME1036 Tested against Clinical Strains of Community-Acquired Methicillin-Resistant Staphylococcus aureus

Ronald N. Jones, T. Fritsche, H. Sader, 2008, Antimicrobial Agents and Chemotherapy.

Molecular Characterization of Staphylococcus aureus Isolates from a 2005 Clinical Trial of Uncomplicated Skin and Skin Structure Infections

Ronald N. Jones, L. Deshpande, G. Notario, 2007, Antimicrobial Agents and Chemotherapy.

Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: a sample of North American isolates.

Ronald N. Jones, T. Fritsche, H. Sader, 2004, Diagnostic microbiology and infectious disease.

Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia.

Ronald N. Jones, M. Jacobs, H. Sader, 2010, International journal of antimicrobial agents.

Antimicrobial susceptibility testing (AST): A review of changing trends, quality control guidelines, test accuracy, and recommendation for the testing of β-lactam drugs☆

Ronald N. Jones, 1983 .

Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis.

Ronald N. Jones, G. Drusano, J. Anon, 2008, Diagnostic microbiology and infectious disease.

Pharmacology Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis

Ronald N. Jones, G. Drusano, J. Anon, 2008 .

Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis.

Ronald N. Jones, M. Piedmonte, J. Anon, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains

Ronald N. Jones, T. Fritsche, H. Sader, 2005, Antimicrobial Agents and Chemotherapy.

Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.

Ronald N. Jones, M. Pfaller, 2002, Diagnostic microbiology and infectious disease.

In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-1999).

Ronald N. Jones, J. Turnidge, M. Pfaller, 2002, Diagnostic microbiology and infectious disease.

Noninvasive Streptococcus pneumoniae Serotypes Recovered from Hospitalized Adult Patients in the United States in 2009 to 2012

Ronald N. Jones, D. Farrell, R. Isturiz, 2015, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of single‐dose ceftaroline fosamil in children with cystic fibrosis

Ronald N. Jones, E. Capparelli, J. Le, 2017, Pediatric pulmonology.

In vitro activity of ceftaroline tested against isolates from the Asia-Pacific region and South Africa (2011).

Ronald N. Jones, H. Sader, R. Flamm, 2014, Journal of global antimicrobial resistance.

Ceftaroline activity tested against uncommonly isolated Gram-positive pathogens: report from the SENTRY Antimicrobial Surveillance Program (2008-2011).

Ronald N. Jones, H. Sader, R. Flamm, 2014, International journal of antimicrobial agents.

Antimicrobial Activity of Ceftaroline Tested against Staphylococci with Reduced Susceptibility to Linezolid, Daptomycin, or Vancomycin from U.S. Hospitals, 2008 to 2011

Ronald N. Jones, H. Sader, R. Flamm, 2013, Antimicrobial Agents and Chemotherapy.

Antimicrobial Activity of Ceftaroline-Avibactam Tested against Clinical Isolates Collected from U.S. Medical Centers in 2010-2011

Ronald N. Jones, H. Sader, R. Flamm, 2013, Antimicrobial Agents and Chemotherapy.

Ceftaroline applications for therapy in the United States.

Ronald N. Jones, G. Corey, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antimicrobial Activity of Pruliﬂoxacin Tested against a Worldwide Collection of Gastroenteritis-Producing Pathogens, Including Those Causing Traveler’s Diarrhea (cid:1)

Ronald N. Jones, T. Fritsche, D. Biedenbach, 2009 .

Prevalence and antimicrobial susceptibility patterns among gastroenteritis-causing pathogens recovered in Europe and Latin America and Salmonella isolates recovered from bloodstream infections in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (2003).

Ronald N. Jones, M. Toleman, T. Fritsche, 2006, International journal of antimicrobial agents.

Methodsand Three Automated Testing Staphylococcus aureus: Comparison of Testing for Methicillin-Resistant Evaluation of Vancomycin Susceptibility

Ronald N. Jones, H. Sader, C. Vidaillac, 2014 .

Evaluation of Vancomycin Susceptibility Testing for Methicillin-Resistant Staphylococcus aureus: Comparison of Etest and Three Automated Testing Methods

Ronald N. Jones, P. Rhomberg, A. Wanger, 2013, Journal of Clinical Microbiology.

Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).

Ronald N. Jones, B. Goldstein, T. Fritsche, 2006, Diagnostic microbiology and infectious disease.

Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms.

Ronald N. Jones, H. Sader, J. Streit, 2004, The Journal of antimicrobial chemotherapy.

ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries.

Ronald N. Jones, K. Yanagihara, S. Kohno, 2009, Diagnostic microbiology and infectious disease.

Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).

Ronald N. Jones, D. Farrell, H. Sader, 2014, International journal of antimicrobial agents.

Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections.

Ronald N. Jones, T. Fritsche, 2004, International journal of antimicrobial agents.

In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.

Ronald N. Jones, T. Fritsche, J. T. Kirby, 2004, Diagnostic microbiology and infectious disease.

Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates.

Ronald N. Jones, T. Fritsche, H. Sader, 2004, Diagnostic microbiology and infectious disease.

Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).

Ronald N. Jones, P. Rhomberg, T. Fritsche, 2006, Diagnostic microbiology and infectious disease.

Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods.

Ronald N. Jones, M. Castanheira, M. Pfaller, 2011, The Journal of antimicrobial chemotherapy.

Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009).

Ronald N. Jones, M. Castanheira, M. Pfaller, 2011, Diagnostic microbiology and infectious disease.

Potency of Anidulafungin Compared to Nine Other Antifungal Agents Tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Results from the Global SENTRY Antimicrobial Surveillance Program (2008)

Ronald N. Jones, M. Castanheira, S. Messer, 2010, Journal of Clinical Microbiology.

Low Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida Strains

Ronald N. Jones, M. Castanheira, M. Pfaller, 2010, Antimicrobial Agents and Chemotherapy.

Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014).

Ronald N. Jones, M. Castanheira, D. Farrell, 2015, Diagnostic microbiology and infectious disease.

Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013

Ronald N. Jones, M. Castanheira, D. Farrell, 2015, Antimicrobial Agents and Chemotherapy.

Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).

Ronald N. Jones, P. Rhomberg, 2007, Diagnostic microbiology and infectious disease.

Emerging metallo-beta-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program.

Ronald N. Jones, M. Toleman, T. Walsh, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Emerging epidemic of metallo-β-lactamase-mediated resistances

Ronald N. Jones, M. Toleman, T. Walsh, 2005 .

Emerging epidemic of metallo-beta-lactamase-mediated resistances.

Ronald N. Jones, M. Toleman, T. Walsh, 2005, Diagnostic microbiology and infectious disease.

Emergence of the Extended-Spectrum β-Lactamase GES-1 in a Pseudomonas aeruginosa Strain from Brazil: Report from the SENTRY Antimicrobial Surveillance Program

Ronald N. Jones, M. Castanheira, T. Walsh, 2004, Antimicrobial Agents and Chemotherapy.

Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011).

Ronald N. Jones, H. Sader, R. Mendes, 2013, Diagnostic microbiology and infectious disease.

Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998-2009).

Ronald N. Jones, D. Farrell, Gary J. Moet, 2010, Diagnostic microbiology and infectious disease.

Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).

Ronald N. Jones, T. Fritsche, H. Sader, 2007, Diagnostic microbiology and infectious disease.

Global Epidemiology of Antimicrobial Resistance among Community-Acquired and Nosocomial Pathogens: A Five-Year Summary from the SENTRY Antimicrobial Surveillance Program (1997-2001)

Ronald N. Jones, 2003, Seminars in respiratory and critical care medicine.

Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates

Ronald N. Jones, M. Castanheira, P. Rhomberg, 2016, The Journal of antimicrobial chemotherapy.

Mutation-Driven β-Lactam Resistance Mechanisms among Contemporary Ceftazidime-Nonsusceptible Pseudomonas aeruginosa Isolates from U.S. Hospitals

Ronald N. Jones, M. Castanheira, D. Farrell, 2014, Antimicrobial Agents and Chemotherapy.

OprD loss and hyperexpression of AmpC

Ronald N. Jones, M. Castanheira, D. Farrell, 2014 .

Comment on: Linezolid resistance in coagulase-negative staphylococci2

Ronald N. Jones, T. Fritsche, H. Sader, 2006 .

In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci.

Ronald N. Jones, A. Mutnick, D. Biedenbach, 2002, The Journal of antimicrobial chemotherapy.

In vitro evaluation of contemporary β-lactam drugs tested against viridans group and β-haemolytic streptococci

Ronald N. Jones, M. Pfaller, 1997 .

Methicillin-Resistant Staphylococcus aureus Outbreak in a Veterinary Teaching Hospital: Potential Human-to-Animal Transmission

Ronald N. Jones, W. Kloos, J. Caron, 1999, Journal of Clinical Microbiology.

E test, an antimicrobial susceptibility testing method with broad clinical and epidemiologic application

Ronald N. Jones, Martha L. Sanchez, 1992 .

Evaluation of the contemporary occurrence rates of metallo-beta-lactamases in multidrug-resistant Gram-negative bacilli in Japan: report from the SENTRY Antimicrobial Surveillance Program (1998-2002).

Ronald N. Jones, J. Turnidge, Y. Hirakata, 2004, Diagnostic microbiology and infectious disease.

Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns.

Ronald N. Jones, H. Sader, Juliana B Silva, 2002, Diagnostic microbiology and infectious disease.

First Description of Klebsiella pneumoniae Harboring CTX-M β-Lactamases (CTX-M-14 and CTX-M-3) in Taiwan

Ronald N. Jones, M. Pfaller, P. Winokur, 2002, Antimicrobial Agents and Chemotherapy.

Antimicrobial susceptibility of bacteria causing urinary tract infections in Latin American hospitals: results from the SENTRY Antimicrobial Surveillance Program (1997).

Ronald N. Jones, T. Barrett, M. Pfaller, 1999, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Phenotypic and genotypic characterizations of chinese strains of Escherichia coli producing extended-spectrum β-lactamases

Ronald N. Jones, M. Pfaller, P. Winokur, 1999 .

Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value

Ronald N. Jones, H. Sader, R. Flamm, 2014, Journal of chemotherapy.

Antimicrobial susceptibility of inducible AmpC beta-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000.

Ronald N. Jones, M. Pfaller, 2002, International journal of antimicrobial agents.

Evaluation of the in vitro antimicrobial activity of cefepime compared to other broad-spectrum β-lactams tested against recent clinical isolates from 10 Chinese hospitals

Ronald N. Jones, Yingchun Xu, D. Biedenbach, 1999 .

Inducible β-lactamase-mediated resistance to third-generation cephalosporins

Ronald N. Jones, F. Baquero, G. Privitera, 1997 .

Candida Bloodstream Infections: Comparison of Species Distributions and Antifungal Resistance Patterns in Community-Onset and Nosocomial Isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009

Ronald N. Jones, M. Castanheira, M. Pfaller, 2010, Antimicrobial Agents and Chemotherapy.

Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).

Ronald N. Jones, M. Castanheira, M. Pfaller, 2011, International journal of antimicrobial agents.

Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009).

Ronald N. Jones, D. Farrell, H. Sader, 2010, Diagnostic microbiology and infectious disease.

Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).

Ronald N. Jones, H. Sader, R. Mendes, 2010, International journal of antimicrobial agents.

Daptomycin activity tested against linezolid-nonsusceptible gram-positive clinical isolates.

Ronald N. Jones, H. Sader, R. Mendes, 2009, Microbial drug resistance.

Multicenter Evaluation of the In Vitro Activity of Six Broad-Spectrum β-Lactam Antimicrobial Agents in Puerto Rico

Ronald N. Jones, M. Pfaller, G. Doern, 1998 .

In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013).

Ronald N. Jones, M. Castanheira, M. Huband, 2016, International journal of antimicrobial agents.

Regional data analysis of Candida non‐albicans strains collected in United States medical sites over a 6‐year period, 2006–2011

Ronald N. Jones, M. Castanheira, M. Pfaller, 2014, Mycoses.

Omiganan Pentahydrochloride (MBI 226), a Topical 12-Amino-Acid Cationic Peptide: Spectrum of Antimicrobial Activity and Measurements of Bactericidal Activity

Ronald N. Jones, R. Rennie, H. Sader, 2004, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014

Ronald N. Jones, M. Castanheira, M. Huband, 2016, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).

Ronald N. Jones, M. Castanheira, D. Farrell, 2014, The Journal of antimicrobial chemotherapy.

Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Organisms Collected from U.S. Medical Centers in 2012

Ronald N. Jones, M. Castanheira, D. Farrell, 2013, Antimicrobial Agents and Chemotherapy.

Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries.

Ronald N. Jones, T. Fritsche, H. Sader, 2007, Diagnostic microbiology and infectious disease.

Geographic Variations in Species Distribution and Echinocandin and Azole Antifungal Resistance Rates among Candida Bloodstream Infection Isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009)

Ronald N. Jones, M. Castanheira, M. Pfaller, 2010, Journal of Clinical Microbiology.

Oral beta-lactams applied to uncomplicated infections of skin and skin structures.

Ronald N. Jones, M. Jacobs, P. Giordano, 2007, Diagnostic microbiology and infectious disease.

Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp.

Ronald N. Jones, M. Castanheira, P. Rhomberg, 2014, Diagnostic microbiology and infectious disease.

Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents.

Ronald N. Jones, M. Castanheira, D. Farrell, 2017, Journal of global antimicrobial resistance.

Cefdinir: an oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections

Ronald N. Jones, H. Sader, 2007, Expert review of anti-infective therapy.

Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions.

Ronald N. Jones, T. Fritsche, H. Sader, 2006, International journal of antimicrobial agents.

Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012).

Ronald N. Jones, D. Farrell, H. Sader, 2014, The Journal of antimicrobial chemotherapy.

Patients Isolates from Cystic Fibrosis aeruginosa Pseudomonas Susceptibility Testing of Methodologies for Antimicrobial Comparison of Agar Diffusion

Ronald N. Jones, L. Saiman, J. Burns, 2000 .

Update on the cefdinir spectrum and potency against pathogens isolated from uncomplicated skin and soft tissue infections in North America: are we evaluating the orally administered cephalosporins correctly?

Ronald N. Jones, H. Sader, 2006, Diagnostic microbiology and infectious disease.

Activity of Ceftaroline Against Recent Emerging Serotypes of Streptococcus 1

Ronald N. Jones, M. Jacobs, H. Sader, 2010 .

Identification and Antimicrobial Susceptibility of 250 Bacteroides fragilis Subspecies Tested by Broth Microdilution Methods

Ronald N. Jones, P. Fuchs, 1976, Antimicrobial Agents and Chemotherapy.

Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options.

Ronald N. Jones, M. Castanheira, R. Mendes, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program.

Ronald N. Jones, M. Castanheira, J. Turnidge, 2008, The Journal of antimicrobial chemotherapy.

Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007).

Ronald N. Jones, P. Rhomberg, H. Sader, 2009, Diagnostic microbiology and infectious disease.

Complete Sequence of p07-406, a 24,179-Base-Pair Plasmid Harboring the blaVIM-7 Metallo-β-Lactamase Gene in a Pseudomonas aeruginosa Isolate from the United States

Ronald N. Jones, P. Bennett, M. Toleman, 2008, Antimicrobial Agents and Chemotherapy.

Integron Carrying a Novel Metallo-β-Lactamase Gene, blaIMP-16, and a Fused Form of Aminoglycoside-Resistant Gene aac(6′)-30/aac(6′)-Ib′: Report from the SENTRY Antimicrobial Surveillance Program

Ronald N. Jones, M. Toleman, T. Walsh, 2004, Antimicrobial Agents and Chemotherapy.

Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Burkholderia cepacia species complex isolates from a global surveillance program (2013).

Ronald N. Jones, M. Castanheira, R. Flamm, 2016, Diagnostic microbiology and infectious disease.

Mechanisms of Resistance, Clonal Expansion, and Increasing Prevalence of Acinetobacter baumannii Strains Displaying Elevated Tigecycline MIC Values in Latin America.

Ronald N. Jones, M. Castanheira, A. Gales, 2016, Microbial drug resistance.

Potency and Spectrum of Activity of AN3365, a Novel Boron-Containing Protein Synthesis Inhibitor, Tested against Clinical Isolates of Enterobacteriaceae and Nonfermentative Gram-Negative Bacilli

Ronald N. Jones, H. Sader, R. Mendes, 2013, Antimicrobial Agents and Chemotherapy.

Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.

Ronald N. Jones, P. Rhomberg, J. T. Kirby, 2008, Diagnostic microbiology and infectious disease.

Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.

Ronald N. Jones, T. Fritsche, H. Sader, 2005, Diagnostic microbiology and infectious disease.

Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents.

Ronald N. Jones, T. Fritsche, H. Sader, 2005, Diagnostic microbiology and infectious disease.

Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp.

Ronald N. Jones, H. Sader, 2005, International journal of antimicrobial agents.

Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.

Ronald N. Jones, T. Fritsche, H. Sader, 2005, Diagnostic microbiology and infectious disease.

Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003).

Ronald N. Jones, P. Rhomberg, T. Fritsche, 2004, Diagnostic microbiology and infectious disease.

Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.

Ronald N. Jones, T. Fritsche, H. Sader, 2004, The Journal of antimicrobial chemotherapy.

Frequency of fks Mutations among Candida glabrata Isolates from a 10-Year Global Collection of Bloodstream Infection Isolates

Ronald N. Jones, M. Castanheira, M. Pfaller, 2013, Antimicrobial Agents and Chemotherapy.

Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance

Ronald N. Jones, M. Castanheira, M. Pfaller, 2013, Journal of Clinical Microbiology.

In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012

Ronald N. Jones, M. Castanheira, M. Pfaller, 2015, Mycoses.

Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections.

Ronald N. Jones, M. Castanheira, M. Pfaller, 2014, International journal of antimicrobial agents.

In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method.

Ronald N. Jones, M. Castanheira, M. Pfaller, 2011, Diagnostic microbiology and infectious disease.

Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against Fusarium and Scedosporium Species Identified Using Molecular Methods

Ronald N. Jones, M. Castanheira, J. Guarro, 2011, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of a Novel Broad-Spectrum Antifungal, E1210, Tested against Aspergillus spp. Determined by CLSI and EUCAST Broth Microdilution Methods

Ronald N. Jones, M. Castanheira, M. Pfaller, 2011, Antimicrobial Agents and Chemotherapy.

Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries.

Ronald N. Jones, M. Castanheira, L. Deshpande, 2014, The Journal of antimicrobial chemotherapy.

Performance of BD Max StaphSR for Screening of Methicillin-Resistant Staphylococcus aureus Isolates among a Contemporary and Diverse Collection from 146 Institutions Located in Nine U.S. Census Regions: Prevalence of mecA Dropout Mutants

Ronald N. Jones, P. Rhomberg, D. Farrell, 2015, Journal of Clinical Microbiology.

Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014).

Ronald N. Jones, M. Castanheira, H. Sader, 2017, Diagnostic microbiology and infectious disease.

Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014)

Ronald N. Jones, R. Mendes, J. Schuchert, 2016, Antimicrobial Agents and Chemotherapy.

247Antimicrobial Activity of Ceftolozane/Tazobactam Tested against Gram-negative Bacterial Isolates from Hospitalized Patients with Pneumonia in United States Hospitals (2013)

Ronald N. Jones, D. Farrell, H. Sader, 2014, Open Forum Infectious Diseases.

Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).

Ronald N. Jones, D. Farrell, H. Sader, 2014, The Journal of infection.

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)

Ronald N. Jones, D. Farrell, H. Sader, 2013, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs).

Ronald N. Jones, S. Paukner, H. Sader, 2012, The Journal of antimicrobial chemotherapy.

Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.

Ronald N. Jones, T. Fritsche, H. Sader, 2006, The Journal of antimicrobial chemotherapy.

Increased antimicrobial susceptibility profiles among polymyxin-resistant Acinetobacter baumannii clinical isolates.

Ronald N. Jones, T. Fritsche, H. Sader, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results.

Ronald N. Jones, Gary J. Moet, H. Sader, 2010, Diagnostic microbiology and infectious disease.

Quality Control Guidelines for MIC Susceptibility Testing of Omiganan Pentahydrochloride (MBI 226), a Novel Antimicrobial Peptide

Ronald N. Jones, T. Fritsche, T. Anderegg, 2004, Journal of Clinical Microbiology.

Summary of Ceftaroline Activity against Pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program

Ronald N. Jones, D. Farrell, H. Sader, 2012, Antimicrobial Agents and Chemotherapy.

Multicenter Evaluation of the Etest and Disk Diffusion Methods for Differentiating Daptomycin-Susceptible from Non-Daptomycin-Susceptible Staphylococcus aureus Isolates

Ronald N. Jones, J. Mcgowan, F. Tenover, 2006, Journal of Clinical Microbiology.

WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant &bgr;-lactamases

Ronald N. Jones, M. Castanheira, P. Rhomberg, 2017, The Journal of antimicrobial chemotherapy.

Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010-2013).

Ronald N. Jones, M. Castanheira, D. Farrell, 2015, Diagnostic microbiology and infectious disease.

Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011).

Ronald N. Jones, D. Farrell, H. Sader, 2014, Diagnostic microbiology and infectious disease.

Prevalent against Isolates Producing the Most Ceftazidime-Avibactam Activity Tested Census Regions and among Enterobacteriaceae in the Nine U . S .-Lactamases

Ronald N. Jones, M. Castanheira, K. Krause, 2014 .

Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae.

Ronald N. Jones, M. Castanheira, H. Sader, 2010, Microbial drug resistance.

Emergence of cefepime-resistance in Klebsiella oxytoca clinical isolate due to alteration in the outer membrane permeability

Ronald N. Jones, M. Tuohy, A. Gales, 2000 .

Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014)

Ronald N. Jones, R. Mendes, R. Flamm, 2016, Antimicrobial Agents and Chemotherapy.

Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011).

Ronald N. Jones, H. Sader, R. Flamm, 2013, Diagnostic microbiology and infectious disease.

Integron Carrying a Novel Metallo- (cid:2) -Lactamase Gene, bla IMP-16 , and a Fused Form of Aminoglycoside-Resistant Gene aac(6 (cid:3) )-30/aac(6 (cid:3) )-Ib (cid:3) : Report from the SENTRY Antimicrobial Surveillance Program

Ronald N. Jones, M. Toleman, T. Walsh, 2004 .

Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.

Ronald N. Jones, M. Castanheira, D. Livermore, 2009, Diagnostic microbiology and infectious disease.

RmtD 16S RNA Methylase in Epidemiologically Unrelated SPM-1-Producing Pseudomonas aeruginosa Isolates from Brazil

Ronald N. Jones, M. Castanheira, T. Fritsche, 2008, Antimicrobial Agents and Chemotherapy.

An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004.

Ronald N. Jones, R. Masterton, P. Turner, 2005, Diagnostic microbiology and infectious disease.

First Isolation of blaVIM-2 in Latin America: Report from the SENTRY Antimicrobial Surveillance Program

Ronald N. Jones, M. Castanheira, M. Toleman, 2004, Antimicrobial Agents and Chemotherapy.

Pseudomonas aeruginosa strains harbouring an unusual blaVIM-4 gene cassette isolated from hospitalized children in Poland (1998-2001).

Ronald N. Jones, P. Bennett, M. Toleman, 2004, The Journal of antimicrobial chemotherapy.

Pathogen occurrence and antimicrobial resistance trends among urinary tract infection isolates in the Asia-Western Pacific Region: report from the SENTRY Antimicrobial Surveillance Program, 1998-1999.

Ronald N. Jones, J. Turnidge, D. Biedenbach, 2002, International journal of antimicrobial agents.

Tiamulin Activity against Fastidious and Nonfastidious Veterinary and Human Bacterial Isolates: Initial Development of In Vitro Susceptibility Test Methods

Ronald N. Jones, P. Rhomberg, M. Pfaller, 2002, Journal of Clinical Microbiology.

Cefuroxime, a New Parenteral Cephalosporin: Collaborative In Vitro Susceptibility Comparison with Cephalothin Against 5,887 Clinical Bacterial Isolates

Ronald N. Jones, A. Barry, P. Fuchs, 1977, Antimicrobial Agents and Chemotherapy.

Evaluation of Low-Dose, Extended-Interval Clindamycin Regimens against Staphylococcus aureus and Streptococcus pneumoniae Using a Dynamic In Vitro Model of Infection

Ronald N. Jones, M. Klepser, E. Ernst, 1999, Antimicrobial Agents and Chemotherapy.

Global Emergence of Trimethoprim/Sulfamethoxazole Resistance in Stenotrophomonas maltophilia Mediated by Acquisition of sul Genes

Ronald N. Jones, P. Bennett, M. Toleman, 2007, Emerging infectious diseases.

In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): A novel orally administered streptogramin combination

Ronald N. Jones, S. Putnam, David M. Johnson, 1997 .

Oritavancin microbiologic features and activity results from the surveillance program in the United States.

Ronald N. Jones, D. Farrell, H. Sader, 2012, Clinical Infectious Diseases.

Polymyxins: wisdom does not always come with age.

Ronald N. Jones, J. Rotschafer, L. Danziger, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comparative Antimicrobial Characterization of LBM415 (NVP PDF-713), a New Peptide Deformylase Inhibitor of Clinical Importance

Ronald N. Jones, T. Fritsche, R. Cleeland, 2005, Antimicrobial Agents and Chemotherapy.

Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates.

Ronald N. Jones, Gary J. Moet, T. Fritsche, 2004, The Journal of antimicrobial chemotherapy.

Activity of faropenem tested against Neisseria gonorrhoeae isolates including fluoroquinolone-resistant strains.

Ronald N. Jones, N. Janjić, W. Whittington, 2005, Diagnostic microbiology and infectious disease.

Emerging Resistance to Antimicrobial Agents in Gram-Positive Bacteria

Ronald N. Jones, M. Cormican, 2012, Drugs.

Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program.

Ronald N. Jones, Gary J. Moet, T. Fritsche, 2007, Diagnostic microbiology and infectious disease.

In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual gram-positive species.

Ronald N. Jones, D. Biedenbach, T. Anderegg, 2002, Diagnostic microbiology and infectious disease.

Antimicrobial Activity of Ceftaroline Tested Against Streptococci from United States (USA) and European (EU) Medical Centers: Results from the Ceftaroline Surveillance Program

Ronald N. Jones, I. Critchley, D. Biek, 2009 .

Tigecycline (GAR-936) activity against Streptococcus gallolyticus (bovis) and viridans group streptococci.

Ronald N. Jones, Gary J. Moet, Ronald N Jones, 2007, Diagnostic microbiology and infectious disease.

Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.

Ronald N. Jones, T. Fritsche, H. Sader, 2005, Diagnostic microbiology and infectious disease.

Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).

Ronald N. Jones, T. Fritsche, H. Sader, 2005, Diagnostic microbiology and infectious disease.

Reproducibility of dalbavancin MIC test results and an updated surrogate accuracy analysis of vancomycin MIC values to infer dalbavancin susceptibility (2014).

Ronald N. Jones, P. Rhomberg, R. Mendes, 2016, Diagnostic microbiology and infectious disease.

Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin.

Ronald N. Jones, D. Farrell, H. Sader, 2015, Diagnostic microbiology and infectious disease.

Comprehensive update of dalbavancin activity when tested against uncommonly isolated streptococci, Corynebacterium spp., Listeria monocytogenes, and Micrococcus spp. (1357 strains).

Ronald N. Jones, M. Stilwell, 2013, Diagnostic microbiology and infectious disease.

Surveillance of dalbavancin potency and spectrum in the United States (2012).

Ronald N. Jones, H. Sader, R. Flamm, 2013, Diagnostic microbiology and infectious disease.

Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011).

Ronald N. Jones, H. Sader, R. Flamm, 2013, Diagnostic microbiology and infectious disease.

Activities of Dalbavancin against a Worldwide Collection of 81,673 Gram-Positive Bacterial Isolates

Ronald N. Jones, J. Turnidge, H. Sader, 2009, Antimicrobial Agents and Chemotherapy.

Activity of Dalbavancin Tested against Staphylococcus spp. and β-Hemolytic Streptococcus spp. Isolated from 52 Geographically Diverse Medical Centers in the United States

Ronald N. Jones, T. Fritsche, H. Sader, 2007, Journal of Clinical Microbiology.

Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the United States (2013-2014).

Ronald N. Jones, H. Sader, R. Mendes, 2016, Diagnostic microbiology and infectious disease.

Use of In Vitro Vancomycin Testing Results To Predict Susceptibility to Oritavancin, a New Long-Acting Lipoglycopeptide

Ronald N. Jones, J. Turnidge, R. Mendes, 2015, Antimicrobial Agents and Chemotherapy.

Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide.

Ronald N. Jones, H. Sader, R. Mendes, 2014, The Journal of antimicrobial chemotherapy.

Factors Influencing Broth Microdilution Antimicrobial Susceptibility Test Results for Dalbavancin, a New Glycopeptide Agent

Ronald N. Jones, L. Koeth, R. Rennie, 2007, Journal of Clinical Microbiology.

Initial Quality Control Evaluations for Susceptibility Testing of Dalbavancin (BI397), an Investigational Glycopeptide with Potent Gram-Positive Activity

Ronald N. Jones, D. Biedenbach, T. Anderegg, 2003, Journal of Clinical Microbiology.

Historical overview of the cephalosporin spectrum: Four generations of structural evolution

Ronald N. Jones, H. Sader, 1992 .

Interpretive criteria for DU-6859a disk diffusion tests using 5-μg disks

Ronald N. Jones, David M. Johnson, M. Erwin, 1994 .

Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.

Ronald N. Jones, T. Fritsche, H. Sader, 2005, International journal of antimicrobial agents.

Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.

Ronald N. Jones, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Activities of Doripenem (S-4661) against Drug-Resistant Clinical Pathogens

Ronald N. Jones, D. Biedenbach, H. Huynh, 2004, Antimicrobial Agents and Chemotherapy.

Results of the survey of the quality assurance for commercially prepared microbiology media. Update from the College of American Pathologists Microbiology Surveys Program (2001).

Ronald N. Jones, K. Krisher, Deborah S Bird, 2003, Archives of pathology & laboratory medicine.

Oxacillin- and Quinolone-Resistant Staphylococcus Aureus in Sao Paulo, Brazil: A Multicenter Molecular Epidemiology Study

Ronald N. Jones, R. Jones, R. Hollis, 1993, Infection Control & Hospital Epidemiology.

Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms.

Ronald N. Jones, R. Mendes, L. Deshpande, 2014, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Bacterial Pathogens Isolated from Patients with Bloodstream Infection: Frequencies of Occurrence and Antimicrobial Susceptibility Patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)

Ronald N. Jones, M. Pfaller, G. Doern, 1998, Antimicrobial Agents and Chemotherapy.

Activity of gemifloxacin tested against Neisseria gonorrhoeae isolates including antimicrobial-resistant phenotypes.

Ronald N. Jones, T. Fritsche, S. Pottumarthy, 2006, Diagnostic microbiology and infectious disease.

Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots.

Ronald N. Jones, Gary J. Moet, H. Sader, 2009, Diagnostic microbiology and infectious disease.

Comprehensive Investigations of piperacillin/tazobactam (P/T) Generic Formulations Compared to Branded Lots: Studies of 46 Lots from 29 Manufacturers

Ronald N. Jones, 2009 .

In vitro antimicrobial activity of tioconazole and its concentrations in vaginal fluids following topical (vagistat-1 16.5%) application

Ronald N. Jones, M. Bale, D. Hoban, 1993 .

Advances in Antifungal Susceptibility Testing of Candida, 2010–2012

Ronald N. Jones, M. Castanheira, M. Pfaller, 2012, Current Fungal Infection Reports.

In Vitro Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and Molds

Ronald N. Jones, M. Castanheira, P. Rhomberg, 2013, Journal of Clinical Microbiology.

Quality Control Parameters forSusceptibility Tests with30-,ug Netilmicin Disks

Ronald N. Jones, A. Barry, 1983 .

Candida glabrata: Multidrug Resistance and Increased Virulence in a Major Opportunistic Fungal Pathogen

Ronald N. Jones, M. Castanheira, S. Lockhart, 2012, Current Fungal Infection Reports.

Use of the E-test to assess macrolide-lincosamide resistance patterns among peptostreptococcus species

Ronald N. Jones, Martha L. Sanchez, J. L. Croco, 1992 .

In vitro activity of gatifloxacin tested against anaerobic bacteria by reference agar dilution and Etest methods.

Ronald N. Jones, M. Pfaller, M. S. Barrett, 1999, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).

Ronald N. Jones, T. Fritsche, H. Sader, 2004, International journal of antimicrobial agents.

Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001).

Ronald N. Jones, H. Sader, D. Biedenbach, 2003, Diagnostic microbiology and infectious disease.

Antimicrobial Resistance Surveillance and New Drug Development

Ronald N. Jones, P. Rhomberg, H. Sader, 2019, Open forum infectious diseases.

Candida guilliermondii and Other Species of Candida Misidentified as Candida famata: Assessment by Vitek 2, DNA Sequencing Analysis, and Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry in Two Global Antifungal Surveillance Programs

Ronald N. Jones, M. Castanheira, M. Pfaller, 2012, Journal of Clinical Microbiology.

Ronald N. Jones, M. Castanheira, P. Rhomberg, 2014, Mycopathologia.

Activity of Contemporary Antifungal Agents, Including the Novel Echinocandin Anidulafungin, Tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007)

Ronald N. Jones, S. Messer, Gary J. Moet, 2009, Journal of Clinical Microbiology.

The impact of proficiency survey programs on laboratory antimicrobial susceptibility testing

Ronald N. Jones, P. Fuchs, 1984 .

Cefmenoxime (SCE-1365), a new Cephalosporin: In Vitro Activity, Comparison with Other Antimicrobial Agents, Beta-Lactamase Stability, and Disk Diffusion Testing with Tentative Interpretive Criteria

Ronald N. Jones, A. Barry, P. Fuchs, 1981, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity, spectrum and pharmacokinetics of old and new orally administered cephems

Ronald N. Jones, 1988 .

Commentary: revised susceptibility breakpoints: fear, loathing and good science.

Ronald N. Jones, M. Dudley, P. Ambrose, 2013, The Pediatric infectious disease journal.

Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.

Ronald N. Jones, M. Ferraro, W. Craig, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Ceftriaxone: A summary of in vitro antibacterial qualities including recommendations for susceptibility tests with 30-μg disks

Ronald N. Jones, A. Barry, C. Thornsberry, 1983 .

Proposed Quality Control Guidelines

Ronald N. Jones, A. Barry, C. Thornsberry, 2016 .

Antimicrobial Susceptibility Testing of Cefoperazone

Ronald N. Jones, A. Barry, C. Baker, 2003 .

In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and β-lactamase studies

Ronald N. Jones, A. Barry, C. Thornsberry, 1985 .

Susceptibility trends of haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program.

Ronald N. Jones, T. Fritsche, D. M. Johnson, 2003, Diagnostic microbiology and infectious disease.

Influence ofCation Supplements on Activity ofNetilmicin against Pseudomonas aeruginosa InVitro andInVivo

Ronald N. Jones, R. Ferraresi, C. Thornsberry, 1987 .

Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates.

Ronald N. Jones, T. Fritsche, H. Sader, 2005, Diagnostic microbiology and infectious disease.

Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011).

Ronald N. Jones, H. Sader, R. Flamm, 2013, Diagnostic microbiology and infectious disease.

Salmonella spp. isolates causing bloodstream infections in Latin America: report of antimicrobial activity from the SENTRY Antimicrobial Surveillance Program (1997-2000).

Ronald N. Jones, A. Gales, H. Sader, 2002, Diagnostic microbiology and infectious disease.

Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010–2012)

Ronald N. Jones, M. Castanheira, M. Pfaller, 2015, The Journal of Antibiotics.

A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.

Ronald N. Jones, M. Pfaller, D. Diekema, 2009, Diagnostic microbiology and infectious disease.

Selection of a Surrogate Agent (Vancomycin or Teicoplanin) for Initial Susceptibility Testing of Dalbavancin: Results from an International Antimicrobial Surveillance Program

Ronald N. Jones, T. Fritsche, H. Sader, 2006, Journal of Clinical Microbiology.

Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients.

Ronald N. Jones, T. Fritsche, H. Sader, 2009, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).

Ronald N. Jones, Gary J. Moet, T. Fritsche, 2007, Diagnostic microbiology and infectious disease.

Comparison of Amino Acid Decarboxylase and Dihydrolase Results by Moeller, Rapid, and Replicator Plate Methods

Ronald N. Jones, P. Fuchs, Steve Sniderman, 1976, Journal of clinical microbiology.

Characterization of Vancomycin-Heteroresistant Staphylococcus aureus from the Metropolitan Area of Detroit, Michigan, over a 22-Year Period (1986 to 2007)

Ronald N. Jones, M. Rybak, Steven N. Leonard, 2008, Journal of Clinical Microbiology.

CANCER Resistance Surveillance Program: Initial Results from Hematology–Oncology Centers in North America

Ronald N. Jones, A. Mutnick, J. T. Kirby, 2003, The Annals of pharmacotherapy.

Antimicrobial Characterization of CEM-101: Potential Application Against Species Causing Enteritis/Gastroenteritis

Ronald N. Jones, 2008 .

Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000.

Ronald N. Jones, J. Turnidge, A. Mutnick, 2002, Diagnostic microbiology and infectious disease.

Comparative potencies of contemporary generic vancomycin lot: in vitro assay results from nine products and a reference reagent-grade sample.

Ronald N. Jones, H. Sader, R. Flamm, 2013, Diagnostic microbiology and infectious disease.

More potency assay results for generic non-USA lots of piperacillin/tazobactam and initial reports for generic meropenem compounds marketed in the USA.

Ronald N. Jones, H. Sader, R. Flamm, 2013, Diagnostic microbiology and infectious disease.

Determination of MIC Quality Control Ranges for ABT-733, a Novel Ketolide Antimicrobial Agent

Ronald N. Jones, S. Marshall, M. Erwin, 2000, Journal of Clinical Microbiology.

Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program.

Ronald N. Jones, D. Farrell, R. Mendes, 2010, Diagnostic microbiology and infectious disease.

Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli.

Ronald N. Jones, H. Sader, Helio S Sader, 2005, International journal of antimicrobial agents.

Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections.

Ronald N. Jones, T. Fritsche, H. Sader, 2007, International Journal of Antimicrobial Agents.

Klebsiella pneumoniae Isolate from a New York City Hospital Belonging to Sequence Type 258 and Carrying blaKPC-2 and blaVIM-4

Ronald N. Jones, M. Castanheira, S. Jenkins, 2016, Antimicrobial Agents and Chemotherapy.

Detection of Methyltransferases Conferring High-Level Resistance to Aminoglycosides in Enterobacteriaceae from Europe, North America, and Latin America

Ronald N. Jones, M. Castanheira, T. Fritsche, 2008, Antimicrobial Agents and Chemotherapy.

Antimicrobial Activities of Tigecycline and Other Broad-Spectrum Antimicrobials Tested against Serine Carbapenemase- and Metallo-β-Lactamase-Producing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program

Ronald N. Jones, M. Castanheira, T. Fritsche, 2007, Antimicrobial Agents and Chemotherapy.

Effects of breakpoint changes on carbapenem susceptibility rates of Enterobacteriaceae: Results from the SENTRY Antimicrobial Surveillance Program, United States, 2008 to 2012

Ronald N. Jones, R. Rennie, 2014, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

effects of breakpoint changes on carbapenem susceptibility rates of Enterobacteriaceae : results from the Sentr Y antimicrobial Surveillance program,

Ronald N. Jones, R. Rennie, 2014 .

Klebsiella pneumoniae Carbapenemase-Producing Enterobacteriaceae Testing Susceptible to Cefepime by Reference Methods

Ronald N. Jones, M. Castanheira, R. C. Picão, 2013, Journal of Clinical Microbiology.

Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America.

Ronald N. Jones, P. Rhomberg, 2003, Diagnostic microbiology and infectious disease.

Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem.

Ronald N. Jones, T. Fritsche, H. Sader, 2007, Diagnostic microbiology and infectious disease.

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model

Ronald N. Jones, M. Castanheira, S. Bhavnani, 2016, Antimicrobial Agents and Chemotherapy.

Characterization of the Pharmacokinetics-Pharmacodynamics of Tazobactam in 1 Combination with Piperacillin in an In Vitro Infection Model 2

Ronald N. Jones, M. Castanheira, S. Bhavnani, 2016 .

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in an In Vitro Infection Model

Ronald N. Jones, M. Castanheira, S. Bhavnani, 2013, Antimicrobial Agents and Chemotherapy.

Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology/oncology patients: report from the Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance Program (North America).

Ronald N. Jones, T. Fritsche, J. T. Kirby, 2006, Diagnostic microbiology and infectious disease.

Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12).

Ronald N. Jones, R. Mendes, R. Flamm, 2014, The Journal of antimicrobial chemotherapy.

An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011.

Ronald N. Jones, H. Sader, R. Mendes, 2013, Diagnostic microbiology and infectious disease.

Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.

Ronald N. Jones, D. Farrell, R. Flamm, 2012, International journal of antimicrobial agents.

Determination of Disk Diffusion and MIC Quality Control Guidelines for JNJ-Q2, a Novel Quinolone

Ronald N. Jones, J. E. Ross, Lisa C. Liverman, 2011, Journal of Clinical Microbiology.

JNJ-Q2, a New Fluoroquinolone with Potent In Vitro Activity against Staphylococcus aureus, Including Methicillin- and Fluoroquinolone-Resistant Strains

Ronald N. Jones, D. Farrell, D. Biedenbach, 2011, Antimicrobial Agents and Chemotherapy.

First Report of Staphylococcal Clinical Isolates in Mexico with Linezolid Resistance Caused by cfr: Evidence of In Vivo cfr Mobilization

Ronald N. Jones, R. Mendes, E. Rodriguez-Noriega, 2010, Journal of Clinical Microbiology.

First Report of cfr-Mediated Resistance to Linezolid in Human Staphylococcal Clinical Isolates Recovered in the United States

Ronald N. Jones, M. Castanheira, R. Mendes, 2008, Antimicrobial Agents and Chemotherapy.

Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.

Ronald N. Jones, T. Fritsche, H. Sader, 2007, International journal of antimicrobial agents.

Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.

Ronald N. Jones, T. Fritsche, H. Sader, 2005, Diagnostic microbiology and infectious disease.

Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific.

Ronald N. Jones, J. Turnidge, J. Bell, 2003, The Journal of antimicrobial chemotherapy.

Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox(R) antimicrobial potency study in Latin America (LA-ZAPS).

Ronald N. Jones, F. Rossi, D. Biedenbach, 2002, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program.

Ronald N. Jones, Lillian V. Lee, P. Della‐Latta, 2002, Diagnostic microbiology and infectious disease.

Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).

Ronald N. Jones, T. Fritsche, H. Sader, 2007, Diagnostic microbiology and infectious disease.

Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003).

Ronald N. Jones, T. Fritsche, H. Sader, 2006, Diagnostic microbiology and infectious disease.

Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST)

Ronald N. Jones, G. Drusano, D. Andes, 2019, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012).

Ronald N. Jones, D. Farrell, H. Sader, 2014, Diagnostic microbiology and infectious disease.

Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001).

Ronald N. Jones, H. Sader, M. Beach, 2003, International journal of antimicrobial agents.

In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program.

Ronald N. Jones, D. Farrell, R. Mendes, 2015, Diagnostic microbiology and infectious disease.

Ceftaroline Activity against Bacterial Pathogens Frequently Isolated in U.S. Medical Centers: Results from Five Years of the AWARE Surveillance Program

Ronald N. Jones, D. Farrell, H. Sader, 2015, Antimicrobial Agents and Chemotherapy.

Carbapenem susceptibility discords among Acinetobacter isolates.

Ronald N. Jones, P. Rhomberg, T. Fritsche, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

In vitro evaluation of cefepime and other broad-spectrum β-lactams in Taiwan medical centers

Ronald N. Jones, D. Biedenbach, David M. Johnson, 1999 .

Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.

Ronald N. Jones, T. Fritsche, H. Sader, 2004, Diagnostic microbiology and infectious disease.

Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).

Ronald N. Jones, T. Fritsche, H. Sader, 2009, Diagnostic microbiology and infectious disease.

Antimicrobial Susceptibilities of a Worldwide Collection of Stenotrophomonas maltophilia Isolates Tested against Tigecycline and Agents Commonly Used for S. maltophilia Infections

Ronald N. Jones, D. Farrell, H. Sader, 2010, Antimicrobial Agents and Chemotherapy.

Broth Microdilution Susceptibility Testing of Campylobacter jejuni and the Determination of Quality Control Ranges for Fourteen Antimicrobial Agents

Ronald N. Jones, P. McDermott, T. Fritsche, 2005, Journal of Clinical Microbiology.

Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program

Ronald N. Jones, M. Zervos, M. Pfaller, 2019, Open forum infectious diseases.

Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres.

Ronald N. Jones, D. Farrell, H. Sader, 2010, International journal of antimicrobial agents.

Activity of Ceftaroline-Avibactam Tested against Gram-Negative Organism Populations, including Strains Expressing One or More β-Lactamases and Methicillin-Resistant Staphylococcus aureus Carrying Various Staphylococcal Cassette Chromosome mec Types

Ronald N. Jones, M. Castanheira, D. Farrell, 2012, Antimicrobial Agents and Chemotherapy.

Multiple-Inocula (Replicator) CAMP Test for Presumptive Identification of Group B Streptococci

Ronald N. Jones, P. Fuchs, Carol Christy, 1978, Journal of clinical microbiology.

In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases

Ronald N. Jones, D. Biedenbach, M. Beach, 2001 .

Antimicrobial activity and spectrum of SCH27899 (ziracin®) tested against gram-positive species including recommendations for routine susceptibility testing methods and quality control

Ronald N. Jones, S. Marshall, M. Erwin, 1999 .

Molecular characterization of SPM-1, a novel metallo-beta-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme.

Ronald N. Jones, M. Toleman, T. Walsh, 2002, The Journal of antimicrobial chemotherapy.

Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011-2014).

Ronald N. Jones, M. Castanheira, D. Farrell, 2016, International journal of antimicrobial agents.

Antimicrobial Susceptibility of Acinetobacter calcoaceticus–Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997–2016)

Ronald N. Jones, M. Castanheira, H. Seifert, 2019, Open forum infectious diseases.

Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012.

Ronald N. Jones, D. Farrell, H. Sader, 2014, International journal of antimicrobial agents.

Resistance surveillance program report for selected European nations (2011).

Ronald N. Jones, M. Castanheira, M. Flonta, 2014, Diagnostic microbiology and infectious disease.

Use of a surfactant (polysorbate 80) to improve MIC susceptibility testing results for polymyxin B and colistin.

Ronald N. Jones, P. Rhomberg, H. Sader, 2012, Diagnostic microbiology and infectious disease.

Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011).

Ronald N. Jones, D. Farrell, H. Sader, 2014, Diagnostic microbiology and infectious disease.

Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000).

Ronald N. Jones, A. Gales, H. Sader, 2002, Diagnostic microbiology and infectious disease.

Evaluation of quinolone resistance-determining region mutations and efflux pump expression in Neisseria meningitidis resistant to fluoroquinolones.

Ronald N. Jones, M. Castanheira, D. Farrell, 2012, Diagnostic microbiology and infectious disease.

Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004).

Ronald N. Jones, T. Fritsche, H. Sader, 2006, Microbial drug resistance.

In71, an Enterobacter cloacae blaVIM-1-carrying integron related to In70.2 from Italian Pseudomonas aeruginosa isolates: a SENTRY Antimicrobial Surveillance Program report.

Ronald N. Jones, M. Castanheira, A. Gales, 2007, Microbial drug resistance.

Biochemical Characterization of the Acquired Metallo-β-Lactamase SPM-1 from Pseudomonas aeruginosa

Ronald N. Jones, M. Toleman, T. Walsh, 2003, Antimicrobial Agents and Chemotherapy.

Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRY Antimicrobial Surveillance Program (1997-2000).

Ronald N. Jones, A. Mutnick, D. Biedenbach, 2003, Diagnostic microbiology and infectious disease.

The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin.

Ronald N. Jones, H. Sader, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Disk Diffusion and MIC Quality Control Ranges for BC-3205 and BC-3781, Two Novel Pleuromutilin Antibiotics

Ronald N. Jones, S. Paukner, H. Sader, 2012, Journal of Clinical Microbiology.

Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008).

Ronald N. Jones, P. Rhomberg, Ronald N Jones, 2009, Diagnostic microbiology and infectious disease.

Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.

Ronald N. Jones, D. Farrell, H. Sader, 2014, International journal of antimicrobial agents.

Comparison of Censored Regression and Standard Regression Analyses for Modeling Relationships between Antimicrobial Susceptibility and Patient- and Institution-Specific Variables

Ronald N. Jones, S. Bhavnani, P. Ambrose, 2006, Antimicrobial Agents and Chemotherapy.

Characterization of Methicillin-Resistant Staphylococcus aureus Strains Recovered from a Phase IV Clinical Trial for Linezolid versus Vancomycin for Treatment of Nosocomial Pneumonia

Ronald N. Jones, D. Smyth, D. Farrell, 2012, Journal of Clinical Microbiology.

International multicenter investigation of LB20304, a new fluoronaphthyridone.

Ronald N. Jones, J. Washington, A. von Graevenitz, 1998, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy.

Ronald N. Jones, H. Sader, P. Mariani, 2006, The Journal of antimicrobial chemotherapy.

1-N-(S-3-amino-2-hydroxypropionyl) gentamicin B (Sch 21420): A collaborative in vitro susceptibility comparison with amikacin and gentamicin against 12,984 clinical bacterial isolates

Ronald N. Jones, A. Barry, P. Fuchs, 1978, Current Microbiology.

In Vitro Evaluation of HR810, a New Wide-Spectrum Aminothiazolyl α-Methoxyimino Cephalosporin

Ronald N. Jones, A. Barry, C. Thornsberry, 1984, Antimicrobial Agents and Chemotherapy.

Antimicrobial Activities of Piperacillin-Tazobactam against Haemophilus influenzae Isolates, Including β-Lactamase-Negative Ampicillin-Resistant and β-Lactamase-Positive Amoxicillin- Clavulanate-Resistant Isolates, and Mutations in Their Quinolone Resistance-Determining Regions

Ronald N. Jones, M. Hatta, M. Kaku, 2009, Antimicrobial Agents and Chemotherapy.

BL-S786, A NEW PARENTERAL CEPHALOSPORIN. I

Ronald N. Jones, A. Barry, P. Fuchs, 1977 .

Activity of Gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, Including Susceptibility Test Development, E-Test Comparisons, and Quality Control Guidelines for H. influenzae

Ronald N. Jones, M. Pfaller, D. Biedenbach, 1999, Journal of Clinical Microbiology.

Alternative antimicrobial agents to contemporary treatment of infections cawed by Corynebactaimm parvam ( Propiomibacierimm acmes)

Ronald N. Jones, J. L. Croco, 1992 .

Cefpiramide: comparative in-vitro activity and beta-lactamase stability.

Ronald N. Jones, L. Ayers, R. Jones, 1985, The Journal of antimicrobial chemotherapy.

Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic streptococci as a component of the 2010 SENTRY Antimicrobial Surveillance Program.

Ronald N. Jones, D. Farrell, R. Flamm, 2011, Diagnostic microbiology and infectious disease.

The Genetic Environment of the cfr Gene and the Presence of Other Mechanisms Account for the Very High Linezolid Resistance of Staphylococcus epidermidis Isolate 426-3147L

Ronald N. Jones, A. Mankin, S. Schwarz, 2012, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity of coumermycin and recommendations for disk diffusion tests with 5- and 15-μg disks

Ronald N. Jones, A. Barry, 1987 .

Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Ronald N. Jones, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cefdinir activity against contemporary North American isolates from community-acquired urinary tract infections.

Ronald N. Jones, H. Sader, D. Biedenbach, 2005, International journal of antimicrobial agents.

Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).

Ronald N. Jones, Gary J. Moet, D. Biedenbach, 2004, Diagnostic microbiology and infectious disease.

Frequency of occurrence and antimicrobial susceptibility of Gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009–2011)

Ronald N. Jones, H. Sader, R. Flamm, 2014, Journal of chemotherapy.

Comparison of In Vitro Antimicrobial Activity of Cefamandole and Cefazolin with Cephalothin Against over 8,000 Clinical Bacterial Isolates

Ronald N. Jones, P. Fuchs, 1976, Antimicrobial Agents and Chemotherapy.

The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program

Ronald N. Jones, P. Hsueh, M. Pfaller, 2019, Antimicrobial Agents and Chemotherapy.

SENTRY antimicrobial surveillance program report: Latin American and Brazilian results for 1997 through 2001.

Ronald N. Jones, A. Gales, H. Sader, 2004, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents.

Ronald N. Jones, D. Biedenbach, Kelley A Fedler, 2006, Diagnostic microbiology and infectious disease.

Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype.

Ronald N. Jones, A. Hsiung, T. Fritsche, 2007, Diagnostic microbiology and infectious disease.

Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001-2002).

Ronald N. Jones, T. Fritsche, H. Sader, 2003, Diagnostic microbiology and infectious disease.

In vitro evaluation of U63196-E (AC-1370): Antimicrobial activity, β-lactamase stability, and β-lactamase inhibition

Ronald N. Jones, 1984 .

Quality Control Guidelines for Testing Gram-Negative Control Strains with Polymyxin B and Colistin (Polymyxin E) by Standardized Methods

Ronald N. Jones, J. Swenson, T. Anderegg, 2005, Journal of Clinical Microbiology.

Treatment of methicillin-susceptible Staphylococcus aureus osteoarticular and prosthetic joint infections: using the oxacillin minimum inhibitory concentration to guide appropriate ceftriaxone use.

Ronald N. Jones, Hien M. Nguyen, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antimicrobial activity of ceftaroline and comparator agents when tested against numerous species of coagulase-negative Staphylococcus causing infection in US hospitals.

Ronald N. Jones, D. Farrell, H. Sader, 2016, Diagnostic microbiology and infectious disease.

Antimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative Staphylococcus.

Ronald N. Jones, H. Sader, 2012, Diagnostic microbiology and infectious disease.

Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).

Ronald N. Jones, J. Turnidge, T. Fritsche, 2007, International journal of antimicrobial agents.

Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011–2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin

Ronald N. Jones, D. Farrell, H. Sader, 2016, Journal of chemotherapy.

Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008).

Ronald N. Jones, Gary J. Moet, H. Sader, 2010, Diagnostic microbiology and infectious disease.

Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005).

Ronald N. Jones, M. Pfaller, H. Sader, 2007, Diagnostic microbiology and infectious disease.

Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010).

Ronald N. Jones, D. Farrell, H. Sader, 2011, Diagnostic microbiology and infectious disease.

Daptomycin Activity against Uncommonly Isolated Streptococcal and Other Gram-Positive Species Groups

Ronald N. Jones, D. Farrell, H. Sader, 2013, Antimicrobial Agents and Chemotherapy.

Evaluation of Vancomycin and Daptomycin Potency Trends (MIC Creep) against Methicillin-Resistant Staphylococcus aureus Isolates Collected in Nine U.S. Medical Centers from 2002 to 2006

Ronald N. Jones, D. Snydman, P. Fey, 2010, Antimicrobial Agents and Chemotherapy.

Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13).

Ronald N. Jones, D. Farrell, H. Sader, 2015, The Journal of antimicrobial chemotherapy.

Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals.

Ronald N. Jones, M. Rybak, H. Sader, 2009, The Journal of antimicrobial chemotherapy.

TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens.

Ronald N. Jones, M. Castanheira, Gary J. Moet, 2009, The Journal of antimicrobial chemotherapy.

Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003).

Ronald N. Jones, T. Fritsche, H. Sader, 2004, Diagnostic microbiology and infectious disease.

Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009).

Ronald N. Jones, D. Farrell, H. Sader, 2011, Diagnostic microbiology and infectious disease.

Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009-2013).

Ronald N. Jones, D. Farrell, H. Sader, 2015, Journal of global antimicrobial resistance.

Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes

Ronald N. Jones, P. Rhomberg, D. Farrell, 2011, Antimicrobial Agents and Chemotherapy.

Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA.

Ronald N. Jones, M. Stryjewski, G. Corey, 2015, Diagnostic microbiology and infectious disease.

Antimicrobial activity of LBM415 (NVP PDF-713) tested against pathogenic Neisseria spp. (Neisseria gonorrhoeae and Neisseria meningitidis).

Ronald N. Jones, T. Fritsche, H. Sader, 2005, Diagnostic microbiology and infectious disease.

Relationships between patient- and institution-specific variables and decreased antimicrobial susceptibility of Gram-negative pathogens.

Ronald N. Jones, S. Bhavnani, P. Ambrose, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Infectious Diseases Society of America's 10 × '20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 × '20 a Possibility?

Ronald N. Jones, R. Ebright, G. Nau, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Detection of mcr-1 among Escherichia coli Clinical Isolates Collected Worldwide as Part of the SENTRY Antimicrobial Surveillance Program in 2014 and 2015

Ronald N. Jones, M. Castanheira, R. Mendes, 2016, Antimicrobial Agents and Chemotherapy.

Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections.

Ronald N. Jones, C. Arias, B. Murray, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Multicenter evaluation of antimicrobial resistance to six broad-spectrum β-lactams in Colombia using the Etest method

Ronald N. Jones, M. Pfaller, G. Doern, 1997 .

Relationship between Ceftolozane-Tazobactam Exposure and Selection for Pseudomonas aeruginosa Resistance in a Hollow-Fiber Infection Model

Ronald N. Jones, M. Castanheira, J. McCauley, 2014, Antimicrobial Agents and Chemotherapy.

Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane

Ronald N. Jones, J. McCauley, S. Bhavnani, 2013, Antimicrobial Agents and Chemotherapy.

Relationship between Ceftolozane-Tazobactam Exposure and Drug Resistance Amplification in a Hollow-Fiber Infection Model

Ronald N. Jones, M. Castanheira, J. McCauley, 2013, Antimicrobial Agents and Chemotherapy.

Pharmacodynamics of β-Lactamase Inhibition by NXL104 in Combination with Ceftaroline: Examining Organisms with Multiple Types of β-Lactamases

Ronald N. Jones, M. Castanheira, G. Drusano, 2011, Antimicrobial Agents and Chemotherapy.

β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates

Ronald N. Jones, M. Castanheira, R. Mendes, 2015, Antimicrobial Agents and Chemotherapy.

In vitro evaluation of broad-spectrum β-lactams in the Philippines medical centers: role of fourth-generation cephalosporins

Ronald N. Jones, D. Biedenbach, David M. Johnson, 1999 .

Summation: β-lactam resistance surveillance in the Asia–Western Pacific Region

Ronald N. Jones, 1999 .

In vitro evaluation of cefepime and other broad-spectrum β-lactams in eight medical centers in Thailand

Ronald N. Jones, D. Biedenbach, David M. Johnson, 1999 .

Ceftazidime-Avibactam Activity Tested against Enterobacteriaceae Isolates from U.S. Hospitals (2011 to 2013) and Characterization of β-Lactamase-Producing Strains

Ronald N. Jones, M. Castanheira, H. Sader, 2015, Antimicrobial Agents and Chemotherapy.

Cefepime MIC as a Predictor of the Extended-Spectrum β-Lactamase Type in Klebsiella pneumoniae, Taiwan

Ronald N. Jones, M. Pfaller, P. Winokur, 2002, Emerging infectious diseases.

In vitro evaluation of cefepime and other broad-spectrum β-lactams against bacteria from Indonesian medical centers

Ronald N. Jones, D. Biedenbach, M. Lewis, 1999 .

In vitro evaluation of broad-spectrum β-lactams tested in medical centers in Korea: role of fourth-generation cephalosporins

Ronald N. Jones, D. Biedenbach, M. Lewis, 1999 .

In vitro evaluation of cefepime and other broad-spectrum β-lactams in 22 medical centers in Japan: a phase II trial comparing two annual organism samples

Ronald N. Jones, K. Yamaguchi, D. Biedenbach, 1999 .

In Vitro Evaluations of Aminopenicillin/β-Lactamase Inhibitor Combinations

Ronald N. Jones, 2012, Drugs.

Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011).

Ronald N. Jones, M. Pfaller, H. Sader, 2014, Diagnostic microbiology and infectious disease.

Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).

Ronald N. Jones, H. Sader, R. Flamm, 2013, Diagnostic microbiology and infectious disease.

Geographic and Temporal Patterns of Antimicrobial Resistance in Pseudomonas aeruginosa Over 20 Years From the SENTRY Antimicrobial Surveillance Program, 1997–2016

Ronald N. Jones, A. Tsakris, M. Huband, 2019, Open forum infectious diseases.

Pharmacokinetic and pharmacodynamic profile of ceftobiprole.

Ronald N. Jones, T. Fritsche, N. Patel, 2008, Diagnostic microbiology and infectious disease.

The application of in vitro surveillance data for antibacterial dose selection

Ronald N. Jones, M. Castanheira, H. Sader, 2017, Current opinion in pharmacology.

Accuracy of Sensititre Dry-Form Broth Microdilution Panels to Determine Ceftaroline-Avibactam MIC Values

Ronald N. Jones, P. Rhomberg, K. Krause, 2014 .

Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin–Tazobactam in Obese Patients

Ronald N. Jones, S. C. Forland, J. Veillette, 2021, European Journal of Drug Metabolism and Pharmacokinetics.

Antimicrobial Activity of SCH 27899, Oligosaccharide Member of the Everninomycin Class with a Wide Gram-Positive Spectrum.

Ronald N. Jones, M. Barrett, 1995, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Microbiological Assessment of Polymyxin B Components Tested Alone and in Combination

Ronald N. Jones, J. Rotschafer, P. Rhomberg, 2015, Antimicrobial Agents and Chemotherapy.

Implications of TeqCES: efficacy and safety of gatifloxacin in community-acquired pneumonia.

Ronald N. Jones, L. Mandell, 2002, Diagnostic microbiology and infectious disease.

Antimicrobial activity evaluations of gatifloxacin, a new fluoroquinolone: contemporary pathogen results from a global antimicrobial resistance surveillance program (SENTRY, 1997).

Ronald N. Jones, M. Pfaller, M. Beach, 1999, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Daptomycin Bactericidal Activity and Correlation between Disk and Broth Microdilution Method Results in Testing of Staphylococcus aureus Strains with Decreased Susceptibility to Vancomycin

Ronald N. Jones, T. Fritsche, H. Sader, 2006, Antimicrobial Agents and Chemotherapy.

Microbiological Conclusions

Ronald N. Jones, 2012, Drugs.

Comparison of Agar Diffusion Methodologies for Antimicrobial Susceptibility Testing of Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients

Ronald N. Jones, L. Saiman, J. Burns, 2000, Journal of Clinical Microbiology.

Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections.

Ronald N. Jones, P. Rhomberg, T. Fritsche, 2008, The Journal of antimicrobial chemotherapy.

Antimicrobial Activity of Omiganan Pentahydrochloride against Contemporary Fungal Pathogens Responsible for Catheter-Associated Infections

Ronald N. Jones, P. Rhomberg, T. Fritsche, 2008, Antimicrobial Agents and Chemotherapy.

Update on Fusidic Acid (CEM-102) Tested against Neisseria gonorrhoeae and Chlamydia trachomatis

Ronald N. Jones, S. Kohlhoff, M. Hammerschlag, 2010, Antimicrobial Agents and Chemotherapy.

Nine-Hospital Study Comparing Broth Microdilution and Etest Method Results for Vancomycin and Daptomycin against Methicillin-Resistant Staphylococcus aureus

Ronald N. Jones, P. Rhomberg, H. Sader, 2009, Antimicrobial Agents and Chemotherapy.

In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus.

Ronald N. Jones, P. Rhomberg, T. Fritsche, 2008, Diagnostic microbiology and infectious disease.

Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program.

Ronald N. Jones, William A Craig, W. Craig, 2006, Diagnostic microbiology and infectious disease.

Surveillance in Taiwan Using Molecular Epidemiology for Extended-Spectrum Beta-Lactamase-Producing Klebsiella pneumoniae

Ronald N. Jones, P. Winokur, H. Sader, 2004, Infection Control & Hospital Epidemiology.

Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000).

Ronald N. Jones, A. Gales, Hélio S Sader H, 2002, Diagnostic microbiology and infectious disease.

Quality Control Guidelines for Disk Diffusion and Broth Microdilution Antimicrobial Susceptibility Tests with Seven Drugs for Veterinary Applications

Ronald N. Jones, M. Erwin, B. A. Odland, 2000, Journal of Clinical Microbiology.

Trends in Klebsiella pneumoniae carbapenemase-positive K. pneumoniae in US hospitals: report from the 2007-2009 SENTRY Antimicrobial Surveillance Program.

Ronald N. Jones, R. Lynfield, M. Castanheira, 2013, Diagnostic microbiology and infectious disease.

Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011)

Ronald N. Jones, M. Castanheira, A. Gales, 2013, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005).

Ronald N. Jones, P. Rhomberg, H. Sader, 2006, Diagnostic microbiology and infectious disease.

OXA-163, an OXA-48-Related Class D β-Lactamase with Extended Activity Toward Expanded-Spectrum Cephalosporins

Ronald N. Jones, M. Castanheira, P. Nordmann, 2011, Antimicrobial Agents and Chemotherapy.

Comparative in vitro activity of apalcillin alone and combined with Ro 48-1220, a novel penam β-lactamase inhibitor

Ronald N. Jones, David M. Johnson, 1995 .

Evolution and dissemination of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997-2003).

Ronald N. Jones, M. Toleman, T. Walsh, 2005, Diagnostic microbiology and infectious disease.

The fourth-generation cephalosporins: Antimicrobial activity and spectrum definitions using cefpirome as an example

Ronald N. Jones, H. Sader, 1993 .

LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).

Ronald N. Jones, T. Fritsche, H. Sader, 2007, Diagnostic microbiology and infectious disease.

Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).

Ronald N. Jones, M. Toleman, T. Walsh, 2006, Diagnostic microbiology and infectious disease.

Evaluation of alternative disk diffusion methods for detecting mecA-mediated oxacillin resistance in an international collection of staphylococci: validation report from the SENTRY Antimicrobial Surveillance Program.

Ronald N. Jones, T. Fritsche, S. Pottumarthy, 2005, Diagnostic microbiology and infectious disease.

Comparison of the Vitek Gram-Positive Susceptibility 106 Card and the MRSA-Screen Latex Agglutination Test for Determining Oxacillin Resistance in Clinical Bloodstream Isolates of Staphylococcus aureus

Ronald N. Jones, M. Pfaller, D. Diekema, 2001, Journal of Clinical Microbiology.

Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers.

Ronald N. Jones, D. Farrell, H. Sader, 2016, Surgical infections.

Ceftibuten: a review of antimicrobial activity, spectrum and other microbiologic features

Ronald N. Jones, 1995, The Pediatric infectious disease journal.

Confirmation of extended-spectrum beta-lactamase-producing Serratia marcescens: preliminary report from Taiwan.

Ronald N. Jones, M. Pfaller, L. Wu, 2003, Diagnostic microbiology and infectious disease.

Strategic design of an effective beta-lactamase inhibitor: LN-1-255, a 6-alkylidene-2'-substituted penicillin sulfone.

Ronald N. Jones, R. Bonomo, K. Hujer, 2009, The Journal of biological chemistry.

Determination of Disk Diffusion and MIC Quality Control Guidelines for GSK2140944, a Novel Bacterial Type II Topoisomerase Inhibitor Antimicrobial Agent

Ronald N. Jones, R. Flamm, N. Scangarella-Oman, 2014, Journal of Clinical Microbiology.

Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin America: time for local guidelines?

Ronald N. Jones, S. S. Andrade, A. Gales, 2006, Memorias do Instituto Oswaldo Cruz.

In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004).

Ronald N. Jones, T. Fritsche, H. Sader, 2007, Diagnostic microbiology and infectious disease.

Activity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strains.

Ronald N. Jones, L. Turner, D. Farrell, 2012, Diagnostic microbiology and infectious disease.

Determination of Disk Diffusion and MIC Quality Control Guidelines for Solithromycin, a Novel Fluoroketolide Antibacterial, against Neisseria gonorrhoeae

Ronald N. Jones, S. Riedel, D. Farrell, 2015, Journal of Clinical Microbiology.

CQ-397 and CQ-414: antimicrobial activity and spectrum of two fluoroquinolone---cephalosporin, dual-action compounds with carboxamido bonds.

Ronald N. Jones, David M. Johnson, 1997, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Potency and Bactericidal Activity of Iclaprim against Recent Clinical Gram-Positive Isolates

Ronald N. Jones, T. Fritsche, H. Sader, 2009, Antimicrobial Agents and Chemotherapy.

Activity of Linezolid against 3,251 Strains of Uncommonly Isolated Gram-Positive Organisms: Report from the SENTRY Antimicrobial Surveillance Program

Ronald N. Jones, D. Sheehan, P. Hogan, 2007, Antimicrobial Agents and Chemotherapy.

Nosocomial transmission of Serratia odorifera biogroup. 2: Case report demonstration by macrorestriction analysis of chromosomal DNA using pulsed-field gel electrophoresis.

Ronald N. Jones, T. Perl, L. Herwaldt, 1994 .

Nosocomial Transmission of Serratia odorifera Biogroup 2: Case Report Demonstration by Macrorestriction Analysis of Chromosomal DNA Using Pulsed-Field Gel Electrophoresis

Ronald N. Jones, T. Perl, L. Herwaldt, 1994, Infection Control & Hospital Epidemiology.

Regional Resistance Surveillance Program Results for 12 Asia-Pacific Nations (2011)

Ronald N. Jones, M. Castanheira, J. Turnidge, 2013, Antimicrobial Agents and Chemotherapy.

Changing antimicrobial susceptibility patterns among Streptococcus pneumoniae and Haemophilus influenzae from Brazil: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004).

Ronald N. Jones, M. Castanheira, A. Gales, 2006, Microbial drug resistance.

Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.

Ronald N. Jones, D. Biedenbach, 2009, Diagnostic microbiology and infectious disease.

Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).

Ronald N. Jones, J. Leeds, T. Fritsche, 2006, The Journal of antimicrobial chemotherapy.

Comparison of 2002–2006 OPTAMA Programs for US Hospitals: Focus on Gram-Negative Resistance

Ronald N. Jones, D. Nicolau, J. Crandon, 2009, The Annals of pharmacotherapy.

Serial sinus aspirate samples during high-dose, short-course levofloxacin treatment of acute maxillary sinusitis.

Ronald N. Jones, J. Anon, P. Ambrose, 2007, Diagnostic microbiology and infectious disease.

Several rRNA-Targeting Agents a Phenotype with Cross-Resistance to Streptococcus sanguinis Isolate Displaying

Ronald N. Jones, R. Mendes, L. Deshpande, 2014 .

Streptococcus sanguinis Isolate Displaying a Phenotype with Cross-Resistance to Several rRNA-Targeting Agents

Ronald N. Jones, R. Mendes, L. Deshpande, 2013, Journal of Clinical Microbiology.

Detection of a New cfr-Like Gene, cfr(B), in Enterococcus faecium Isolates Recovered from Human Specimens in the United States as Part of the SENTRY Antimicrobial Surveillance Program

Ronald N. Jones, D. Farrell, R. Mendes, 2015, Antimicrobial Agents and Chemotherapy.

Contemporary antimicrobial activity of triple antibiotic ointment: a multiphased study of recent clinical isolates in the United States and Australia.

Ronald N. Jones, J. Turnidge, D. Biedenbach, 2006, Diagnostic microbiology and infectious disease.

The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008).

Ronald N. Jones, J. Turnidge, D. Farrell, 2010, The Journal of infection.

The Activity of Tedizolid against Gram-positive Pathogens Isolated From Patients in USA Medical Centers: 2014 Surveillance

Ronald N. Jones, D. Farrell, R. Mendes, 2015 .

Update of contemporary antimicrobial resistance rates across China: reference testing results for 12 medical centers (2011).

Ronald N. Jones, M. Castanheira, Y. Ni, 2013, Diagnostic microbiology and infectious disease.

Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007-09).

Ronald N. Jones, M. Castanheira, R. Mendes, 2011, The Journal of antimicrobial chemotherapy.

Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method.

Ronald N. Jones, D. Farrell, H. Sader, 2015, Diagnostic microbiology and infectious disease.

Telavancin In Vitro Activity against a Collection of Methicillin-Resistant Staphylococcus aureus Isolates, Including Resistant Subsets, from the United States

Ronald N. Jones, D. Farrell, H. Sader, 2015, Antimicrobial Agents and Chemotherapy.

Worldwide Appraisal and Update (2010) of Telavancin Activity Tested against a Collection of Gram-Positive Clinical Pathogens from Five Continents

Ronald N. Jones, D. Farrell, H. Sader, 2012, Antimicrobial Agents and Chemotherapy.

Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009).

Ronald N. Jones, D. Farrell, H. Sader, 2012, Diagnostic microbiology and infectious disease.

Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide.

Ronald N. Jones, T. Fritsche, J. Streit, 2004, International journal of antimicrobial agents.

Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013.

Ronald N. Jones, M. Castanheira, D. Farrell, 2015, Diagnostic microbiology and infectious disease.

Antimicrobial Activity of Ceftaroline Tested against Drug-Resistant Subsets of Streptococcus pneumoniae from U.S. Medical Centers

Ronald N. Jones, D. Farrell, H. Sader, 2014, Antimicrobial Agents and Chemotherapy.

Genotypic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole

Ronald N. Jones, D. Farrell, R. Mendes, 2016, Microbial drug resistance.

Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates.

Ronald N. Jones, P. Rhomberg, T. Fritsche, 2004, Diagnostic microbiology and infectious disease.

Comparison of Dalbavancin MIC Values Determined by Etest (AB BIODISK) and Reference Dilution Methods Using Gram-Positive Organisms

Ronald N. Jones, R. Rennie, B. Goldstein, 2006, Journal of Clinical Microbiology.

Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013-2014).

Ronald N. Jones, H. Sader, R. Mendes, 2016, Diagnostic microbiology and infectious disease.

Activities of Tedizolid and Linezolid Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe, and Latin American Countries in 2014

Ronald N. Jones, M. Pfaller, D. Farrell, 2016, Antimicrobial Agents and Chemotherapy.

Validation of a Commercial Dry-Form Broth Microdilution Device (Sensititre) for Testing Tedizolid, a New Oxazolidinone

Ronald N. Jones, P. Rhomberg, N. Holliday, 2014, Journal of Clinical Microbiology.

LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers).

Ronald N. Jones, D. Farrell, H. Sader, 2012, Diagnostic microbiology and infectious disease.

Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005)

Ronald N. Jones, T. Fritsche, H. Sader, 2007, BMC infectious diseases.

Contemporary tetracycline susceptibility testing: doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing Gram-positive pathogens.

Michael L Wilson, Ronald N. Jones, R. Mendes, 2013, Diagnostic microbiology and infectious disease.

Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria.

Michael L Wilson, Ronald N. Jones, M. Weinstein, 2013, Diagnostic microbiology and infectious disease.

Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide.

Ronald N. Jones, T. Fritsche, H. Sader, 2004, Diagnostic microbiology and infectious disease.

Antimicrobial Susceptibility Testing of Clinical Isolates of Bordetella pertussis from Northern California: Report from the SENTRY Antimicrobial Surveillance Program

Ronald N. Jones, M. Pfaller, D. Biedenbach, 2001, Antimicrobial Agents and Chemotherapy.

Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000).

Ronald N. Jones, R. Rennie, A. Mutnick, 2003, Diagnostic microbiology and infectious disease.

Activity of DX-619 Compared to Other Agents against Viridans Group Streptococci, Streptococcus bovis, and Cardiobacterium hominis

Ronald N. Jones, L. Ednie, P. Appelbaum, 2006, Antimicrobial Agents and Chemotherapy.

The Importance of Antimicrobial Resistance Monitoring Worldwide and the Origins of SENTRY Antimicrobial Surveillance Program

Ronald N. Jones, Andrew S Fuhrmeister, 2019, Open forum infectious diseases.

Linezolid surveillance program results for 2008 (LEADER Program for 2008).

Ronald N. Jones, D. Farrell, R. Mendes, 2009, Diagnostic microbiology and infectious disease.

United States resistance surveillance results for linezolid (LEADER Program for 2007).

Ronald N. Jones, M. Castanheira, R. Mendes, 2008, Diagnostic microbiology and infectious disease.

Antimicrobial susceptibility profile among beta-haemolytic Streptococcus spp. collected in the SENTRY Antimicrobial Surveillance Program--North America, 2001.

Ronald N. Jones, D. Biedenbach, J. Stephen, 2003, Diagnostic microbiology and infectious disease.

Cefazolin as a class representative for oral cephalosporins and uncomplicated urinary tract infections caused by indicated Enterobacteriaceae.

Ronald N. Jones, L. Reller, S. Jenkins, 2013, Diagnostic microbiology and infectious disease.

Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel

Ronald N. Jones, M. Castanheira, H. Sader, 2014, Journal of chemotherapy.

Determination of disk diffusion and MIC quality control guidelines for GSK2251052: a novel boron-containing antibacterial.

Ronald N. Jones, N. Scangarella-Oman, J. E. Ross, 2013, Diagnostic microbiology and infectious disease.

Analysis of Vancomycin Susceptibility Testing Results for Presumptive Categorization of Telavancin

Ronald N. Jones, D. Farrell, H. Sader, 2015, Journal of Clinical Microbiology.

Baseline Activity of Telavancin against Gram-Positive Clinical Isolates Responsible for Documented Infections in U.S. Hospitals (2011-2012) as Determined by the Revised Susceptibility Testing Method

Ronald N. Jones, D. Farrell, H. Sader, 2014, Antimicrobial Agents and Chemotherapy.

Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations.

Ronald N. Jones, M. Castanheira, H. Sader, 2017, Diagnostic microbiology and infectious disease.

Revised Reference Broth Microdilution Method for Testing Telavancin: Effect on MIC Results and Correlation with Other Testing Methodologies

Ronald N. Jones, P. Rhomberg, D. Farrell, 2014, Antimicrobial Agents and Chemotherapy.

Antimicrobial Activities of Ceftaroline and Comparator Agents against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections in U.S. Medical Centers, 2008 to 2014

Ronald N. Jones, D. Farrell, H. Sader, 2016, Antimicrobial Agents and Chemotherapy.

Quality Control MIC Ranges Used for Telavancin with Application of a Revised CLSI Reference Broth Microdilution Method

Ronald N. Jones, R. Mendes, J. E. Ross, 2014, Journal of Clinical Microbiology.

In Vitro Activity of Telavancin against a Contemporary Worldwide Collection of Staphylococcus aureus Isolates

Ronald N. Jones, Gary J. Moet, R. Mendes, 2010, Antimicrobial Agents and Chemotherapy.

Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013).

Ronald N. Jones, D. Farrell, H. Sader, 2015, Journal of global antimicrobial resistance.

Validation of Sensititre Dry-Form Broth Microdilution Panels for Susceptibility Testing of Ceftazidime-Avibactam, a Broad-Spectrum-β-Lactamase Inhibitor Combination

Ronald N. Jones, K. Krause, N. Holliday, 2015, Antimicrobial Agents and Chemotherapy.

Accuracy of the Thermo Fisher Scientific (Sensititre™) dry-form broth microdilution MIC product when testing ceftaroline.

Ronald N. Jones, I. Critchley, N. Holliday, 2015, Diagnostic microbiology and infectious disease.

Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections.

Ronald N. Jones, B. Goldstein, T. Fritsche, 2006, Diagnostic microbiology and infectious disease.

Antimicrobial susceptibility studies Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens

Ronald N. Jones, T. Fritsche, H. Sader, 2005 .

Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014

Ronald N. Jones, M. Castanheira, H. Sader, 2016, Antimicrobial Agents and Chemotherapy.

Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.

Ronald N. Jones, M. Castanheira, D. Farrell, 2015, International journal of antimicrobial agents.

Activity of ceftaroline-avibactam tested against contemporary Enterobacteriaceae isolates carrying β-lactamases prevalent in the United States.

Ronald N. Jones, M. Castanheira, H. Sader, 2014, Microbial drug resistance.

Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline Surveillance Program (2012-2014).

Ronald N. Jones, H. Sader, R. Mendes, 2016, Diagnostic microbiology and infectious disease.

Ceftaroline activity tested against viridans group streptococci from US hospitals.

Ronald N. Jones, M. Castanheira, P. Rhomberg, 2016, Diagnostic microbiology and infectious disease.

Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline

Ronald N. Jones, H. Sader, R. Mendes, 2016 .

AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.

Ronald N. Jones, M. Pfaller, D. Farrell, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010).

Ronald N. Jones, D. Farrell, H. Sader, 2013, Diagnostic microbiology and infectious disease.

Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program.

Ronald N. Jones, D. Farrell, H. Sader, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011).

Ronald N. Jones, H. Sader, R. Flamm, 2014, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

Dalbavancin Comparative Activity Tested Against Gram-positive Species in German Medical Centers: Results from the DECIDE Program

Ronald N. Jones, A. Rodloff, F. Schmitz, 2008 .

Factors Inﬂuencing Broth Microdilution Antimicrobial Susceptibility Test Results for Dalbavancin, a New Glycopeptide Agent (cid:1)

Ronald N. Jones, L. Koeth, R. Rennie, 2007 .

Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum.

Brian T. Tsuji, Ronald N. Jones, P. Rhomberg, 2008, Diagnostic microbiology and infectious disease.

Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010).

Ronald N. Jones, D. Farrell, H. Sader, 2013, International journal of antimicrobial agents.

Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency.

Ronald N. Jones, M. Castanheira, D. Farrell, 2016, The Journal of antimicrobial chemotherapy.

Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13).

Ronald N. Jones, M. Castanheira, D. Farrell, 2016, The Journal of antimicrobial chemotherapy.

Report of Linezolid Activity from the Linezolid Experience and Accurate Determination of Resistance (LEADER) Program for 2014: Monitoring Resistance Trends and Mechanisms

Ronald N. Jones, R. Mendes, R. Flamm, 2015 .

Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012).

Ronald N. Jones, D. Farrell, H. Sader, 2014, International journal of antimicrobial agents.

Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010).

Ronald N. Jones, D. Farrell, Gary J. Moet, 2011, Diagnostic microbiology and infectious disease.

Oritavancin Activity against Vancomycin-Susceptible and Vancomycin-Resistant Enterococci with Molecularly Characterized Glycopeptide Resistance Genes Recovered from Bacteremic Patients, 2009-2010

Ronald N. Jones, D. Farrell, H. Sader, 2011, Antimicrobial Agents and Chemotherapy.

Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility

Ronald N. Jones, P. Rhomberg, M. Dudley, 2016, Antimicrobial Agents and Chemotherapy.

Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically indicated species.

Ronald N. Jones, H. Sader, R. Flamm, 2013, Diagnostic microbiology and infectious disease.

Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates.

Ronald N. Jones, H. Sader, R. Mendes, 2016, The Journal of antimicrobial chemotherapy.

Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY Antimicrobial Surveillance Program.

Ronald N. Jones, S. S. Andrade, A. Gales, 2004, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Antimicrobial susceptibility testing of nonenterococcal streptococci

Ronald N. Jones, C. Thornsberry, J. Swenson, 1986 .

Impact of EUCAST, CLSI and USCAST ceftaroline breakpoint changes on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from US medical centres (2015–2018)

Ronald N. Jones, H. Sader, 2020 .

MIC quality control guidelines for doxycycline when testing gram-positive control strains by the reference methods.

Ronald N. Jones, J. E. Ross, 2004, Diagnostic microbiology and infectious disease.

Standardization ofDiskDiffusion andAgarDilution Susceptibility Tests forNeisseria gonorrhoeae: Interpretive Criteria andQuality Control Guidelines forCeftriaxone, Penicillin, Spectinomycin, andTetracycline

Ronald N. Jones, E. Gerlach, T. Gavan, 1989 .

Integrating Escherichia coli Antimicrobial Susceptibility Data from Multiple Surveillance Programs

Ronald N. Jones, S. Levy, T. O'Brien, 2005, Emerging infectious diseases.

In vitro activity of iclaprim and comparison agents tested against Neisseria gonorrhoeae including medium growth supplement effects.

Ronald N. Jones, H. Sader, D. Biedenbach, 2009, Diagnostic microbiology and infectious disease.

Susceptibility Test for Evaluation of Neisseria meningitidis Isolates

Ronald N. Jones, D. Biedenbach, Hughes, 2022 .

The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009).

Ronald N. Jones, M. Castanheira, D. Farrell, 2010, The Journal of infection.

Molecular Typing and Antimicrobial Susceptibility of Vancomycin-Resistant Enterococcus faecium in Brazil

Ronald N. Jones, A. Gales, H. Sader, 2002, Infection Control & Hospital Epidemiology.

Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis.

Ronald N. Jones, J. Alder, G. Thorne, 2005, The Journal of antimicrobial chemotherapy.

In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens.

Ronald N. Jones, J. Turnidge, H. Sader, 2009, Diagnostic microbiology and infectious disease.

Influence of polysorbate-80 when determining the tigecycline MIC by the reference method.

Ronald N. Jones, M. Dowzicky, C. Knapp, 2007, Diagnostic microbiology and infectious disease.

Quality Control Guidelines for Susceptibility Testing of Retapamulin (SB-275833) by Reference and Standardized Methods

Ronald N. Jones, J. E. Ross, 2005, Journal of Clinical Microbiology.

Ceftaroline potency among 9 US Census regions: report from the 2010 AWARE Program.

Ronald N. Jones, D. Farrell, H. Sader, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Codetection of blaOXA-23-Like Gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: Report from the SENTRY Antimicrobial Surveillance Program

Ronald N. Jones, M. Castanheira, J. Turnidge, 2008, Antimicrobial Agents and Chemotherapy.

Clonal Dissemination of Klebsiella pneumoniae Carbapenemase KPC-3 in Long Beach, California

Ronald N. Jones, M. Castanheira, J. Le, 2009, Journal of Clinical Microbiology.

Comment on: role of changes in the L3 loop of the active site in the evolution of enzymatic activity of VIM-type metallo-β-lactamases.

Ronald N. Jones, M. Castanheira, R. Mendes, 2011, The Journal of antimicrobial chemotherapy.

Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests.

Ronald N. Jones, T. Fritsche, H. Sader, 2005, The Journal of antimicrobial chemotherapy.

In Vitro Activity of Fidaxomicin (OPT-80) Tested against Contemporary Clinical Isolates of Staphylococcus spp. and Enterococcus spp

Ronald N. Jones, S. Putnam, J. E. Ross, 2010, Antimicrobial Agents and Chemotherapy.

Quinupristin-Dalfopristin Resistance in Streptococcus pneumoniae: Novel L22 Ribosomal Protein Mutation in Two Clinical Isolates from the SENTRY Antimicrobial Surveillance Program

Ronald N. Jones, I. Morrissey, D. Farrell, 2003, Antimicrobial Agents and Chemotherapy.

In Vitro Evaluation of AZD2563, a Novel Oxazolidinone, against 603 Recent Staphylococcal Isolates

Ronald N. Jones, D. Biedenbach, T. Anderegg, 2002, Antimicrobial Agents and Chemotherapy.

Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006).

Ronald N. Jones, M. Castanheira, H. Sader, 2008, Diagnostic microbiology and infectious disease.

Contemporary Prevalence of BRO β-Lactamases in Moraxella catarrhalis: Report from the SENTRY Antimicrobial Surveillance Program (North America, 1997 to 2004)

Ronald N. Jones, T. Fritsche, H. Sader, 2006, Journal of Clinical Microbiology.

Oritavancin Activity against Staphylococcus aureus Causing Invasive Infections in U.S. and European Hospitals: a 5-Year International Surveillance Program

Ronald N. Jones, D. Farrell, H. Sader, 2014, Antimicrobial Agents and Chemotherapy.

Distribution of fsr among Enterococcus faecalis Isolates from the SENTRY Antimicrobial Surveillance Program

Ronald N. Jones, L. Deshpande, 2003, Journal of Clinical Microbiology.

Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000).

Ronald N. Jones, M. Pfaller, A. Mutnick, 2002, Diagnostic microbiology and infectious disease.

Oritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC Results

Ronald N. Jones, D. Farrell, H. Sader, 2016, Antimicrobial Agents and Chemotherapy.

Baseline Activity of Telavancin When Tested Against Gram-positive Clinical Isolates Responsible for Documented Infections in USA Hospitals (2011-2012) Applying a Revised Susceptibility Testing Method

Ronald N. Jones, D. Farrell, H. Sader, 2014 .

Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, andStreptococcus pneumoniae Isolates from SENTRY Antimicrobial Surveillance Program Medical Centers in Latin America (1999)

Ronald N. Jones, A. Gales, H. Sader, 2001, Antimicrobial Agents and Chemotherapy.

CEM-101 Activity against Gram-Positive Organisms

Ronald N. Jones, M. Castanheira, Leah N. Woosley, 2010, Antimicrobial Agents and Chemotherapy.

CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria.

Ronald N. Jones, M. Castanheira, D. Farrell, 2010, Diagnostic microbiology and infectious disease.

Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results From the SENTRY Antimicrobial Surveillance Program, 1997–2016

Ronald N. Jones, M. Cormican, M. Pfaller, 2019, Open forum infectious diseases.

Apalcillin (PC-904): Spectrum of activity and β-lactamase hydrolysis/inhibition

Ronald N. Jones, A. Barry, C. Thornsberry, 1985 .

Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model.

Ronald N. Jones, Patrick F. Smith, S. Bhavnani, 2006, Diagnostic microbiology and infectious disease.

Pharmacology Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model B

Ronald N. Jones, Patrick F. Smith, S. Bhavnani, 2006 .

Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens.

Ronald N. Jones, M. Vaara, T. Vaara, 2013, The Journal of antimicrobial chemotherapy.

Salmonella bloodstream infections: report from the SENTRY Antimicrobial Surveillance Program (1997-2001).

Ronald N. Jones, M. Toleman, T. Walsh, 2003, International journal of antimicrobial agents.

Determination of CEM-101 Activity Tested against Clinical Isolates of Neisseria meningitidis from a Worldwide Collection

Ronald N. Jones, M. Castanheira, D. Biedenbach, 2010, Antimicrobial Agents and Chemotherapy.

Analysis of Telavancin in vitro Activity Tested Against a USA Collection of Staphylococcus aureus Clinical Isolates Causing Hospital-acquired Pneumonia (2013-2014)

Ronald N. Jones, D. Farrell, H. Sader, 2015 .

Molecular characterization of vancomycin-resistant Enterococcus spp. clinical isolates recovered from hospitalized patients among several medical institutions in China.

Ronald N. Jones, Hong-li Sun, Yingchun Xu, 2012, Diagnostic microbiology and infectious disease.

Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000).

Ronald N. Jones, A. Gales, D. Biedenbach, 2003, International journal of antimicrobial agents.

Re-evaluations of disk diffusion quality control ranges for 11 drugs: report from the QC working group of the national committee for clinical laboratory standards.

Ronald N. Jones, S. Cullen, 2002, International journal of antimicrobial agents.

Interpretive criteria for CI-960 (AM-1091, PD127391) disk diffusion tests using 5-μg disks

Ronald N. Jones, M. Erwin, M. Barrett, 1992 .

Retrospective Molecular Analysis of DIM-1 Metallo-β-Lactamase Discovered in Pseudomonas stutzeri from India in 2000

Ronald N. Jones, M. Castanheira, Leah N. Woosley, 2013, Antimicrobial Agents and Chemotherapy.

Evaluation of Clonality and Carbapenem Resistance Mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus Complex and Enterobacteriaceae Isolates Collected in European and Mediterranean Countries and Detection of Two Novel β-Lactamases, GES-22 and VIM-35

Ronald N. Jones, M. Castanheira, Leah N. Woosley, 2014, Antimicrobial Agents and Chemotherapy.

Carbapenem-Resistant Isolates of Klebsiella pneumoniae in China and Detection of a Conjugative Plasmid (blaKPC-2 plus qnrB4) and a blaIMP-4 Gene

Ronald N. Jones, J. Turnidge, Ziyong Sun, 2007, Antimicrobial Agents and Chemotherapy.

Italian metallo-beta-lactamases: a national problem? Report from the SENTRY Antimicrobial Surveillance Programme.

Ronald N. Jones, M. Toleman, T. Walsh, 2005, The Journal of antimicrobial chemotherapy.

IMP-33, a New IMP Variant Detected in Pseudomonas aeruginosa from Sicily

Ronald N. Jones, M. Castanheira, G. Blandino, 2013, Antimicrobial Agents and Chemotherapy.

Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections.

Ronald N. Jones, D. Biedenbach, David M. Johnson, 2002, Diagnostic microbiology and infectious disease.

Update on the prevalence and genetic characterization of NDM-1-producing Enterobacteriaceae in Indian hospitals during 2010.

Ronald N. Jones, M. Castanheira, Sarah E. Farrell, 2013, Diagnostic microbiology and infectious disease.

High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center.

Ronald N. Jones, M. Castanheira, S. Shelburne, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Haemophilus test medium (HTM) susceptibility methods: Results of evaluations of reproducibility, stability, and medium quality

Ronald N. Jones, G. Doern, J. Hindler, 1993 .

Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.

Ronald N. Jones, M. Castanheira, M. Pfaller, 2017, The Pediatric infectious disease journal.

Molecular and Biochemical Characterization of OXA-45, an Extended-Spectrum Class 2d (cid:2) (cid:3) -Lactamase in Pseudomonas aeruginosa

Ronald N. Jones, M. Toleman, T. Walsh, 2003 .

Ceftaroline Activity Tested Against Bacterial Isolates From Pediatric Patients: Results from the Assessing Worldwide Antimicrobial Resistance and Evaluation Program for the United States (2011–2012)

Ronald N. Jones, D. Farrell, H. Sader, 2014, The Pediatric infectious disease journal.

In Vitro Spectrum of Pexiganan Activity When Tested against Pathogens from Diabetic Foot Infections and with Selected Resistance Mechanisms

Ronald N. Jones, P. Rhomberg, D. Farrell, 2015, Antimicrobial Agents and Chemotherapy.

Bactericidal activity of garenoxacin tested by kill-curve methodology against wild type and QRDR mutant strains of Streptococcus pneumoniae.

Ronald N. Jones, T. Anderegg, 2004, Diagnostic microbiology and infectious disease.

In vitro spectrum of pexiganan activity; bactericidal action and resistance selection tested against pathogens with elevated MIC values to topical agents.

Ronald N. Jones, P. Rhomberg, D. Farrell, 2016, Diagnostic microbiology and infectious disease.

The re-evaluation of the NCCLS ampicillin susceptibility tests with Haemophilus test medium: New interpretive criteria for the disk diffusion method

Ronald N. Jones, G. Doern, J. Hindler, 1992 .

MIC Quality Control Guidelines and Disk Diffusion Test Optimization for CEM-101, a Novel Fluoroketolide

Ronald N. Jones, P. Rhomberg, J. E. Ross, 2009, Journal of Clinical Microbiology.

Contemporary re-evaluation of the activity and spectrum of grepafloxacin tested against isolates in the United States.

Ronald N. Jones, H. Sader, K. A. Gordon, 2003, Diagnostic microbiology and infectious disease.

Performance of Fusidic Acid (CEM-102) Susceptibility Testing Reagents: Broth Microdilution, Disk Diffusion, and Etest Methods as Applied to Staphylococcus aureus

Ronald N. Jones, M. Castanheira, P. Rhomberg, 2010, Journal of Clinical Microbiology.

Post-β-Lactamase-Inhibitor Effect of Tazobactam in Combination with Ceftolozane on Extended-Spectrum-β-Lactamase-Producing Strains

Ronald N. Jones, P. Rhomberg, H. Sader, 2014, Antimicrobial Agents and Chemotherapy.

Significance of Molecular Identification and Antifungal Susceptibility of Clinically Significant Yeasts and Moulds in a Global Antifungal Surveillance Programme

Ronald N. Jones, M. Castanheira, M. Pfaller, 2012, Mycopathologia.

Comparison of Activities of Broad-Spectrum β-Lactam Compounds against 1,128 Gram-Positive Cocci Recently Isolated in Cancer Treatment Centers

Ronald N. Jones, D. Diekema, K. Rolston, 1999, Antimicrobial Agents and Chemotherapy.

Fixed-Ratio Combination Testing of an Echinocandin, Anidulafungin, and an Azole, Voriconazole, against 1,467 Candida Species Isolates

Ronald N. Jones, M. Castanheira, M. Pfaller, 2010, Antimicrobial Agents and Chemotherapy.

P2087 Spectrum and activity of doripenem, an investigational carbapenem, tested against bacterial pathogens recovered from patients hospitalised with pneumonia (Europe; 2004–2006)

Ronald N. Jones, T. Fritsche, H. Sader, 2007 .

P2088 Variations and trends in the activity of doripenem and other broad-spectrum agents against leading bacterial pathogens: results from a European Surveillance Program (2003–2006)

Ronald N. Jones, T. Fritsche, H. Sader, 2007 .

Drug-Resistant Clinical Pathogens Activities of Doripenem ( S-4661 ) against

Ronald N. Jones, J. Douglas, H. Huynh, 2004 .

TR-700, a Novel Oxazolidinone, Tested Against Linezolid-Resistant Gram-positive Species with Well-Characterized Resistance Mechanisms

Ronald N. Jones, 2008 .

In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients.

Ronald N. Jones, D. Farrell, H. Sader, 2016, International journal of antimicrobial agents.

Group B streptococci causing neonatal bloodstream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere.

Ronald N. Jones, P. Rhomberg, M. Pfaller, 2000, American journal of obstetrics and gynecology.

National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic.

Ronald N. Jones, R. Wenzel, M. Edmond, 1998, Diagnostic microbiology and infectious disease.

Susceptibility of Klebsiella spp. to colistin and polymyxin B: results from the SENTRY Antimicrobial Surveillance Program (2006-2009).

Ronald N. Jones, D. Farrell, H. Sader, 2011, International journal of antimicrobial agents.

Antistreptococcal Activity of Gatifloxacin

Ronald N. Jones, D. Biedenbach, M. Beach, 1999, Drugs.

Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-μg) diffusion methods

Ronald N. Jones, M. Pfaller, D. Biedenbach, 1999 .

Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.

Ronald N. Jones, G. Drusano, F. Sörgel, 2010, Diagnostic microbiology and infectious disease.

Antagonism between penicillin and erythromycin against Streptococcus pneumoniae: does it exist?

Ronald N. Jones, L. Deshpande, 2003, Diagnostic microbiology and infectious disease.

In Vitro Activity of RX-P873 against Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii

Ronald N. Jones, P. Rhomberg, D. Farrell, 2015, Antimicrobial Agents and Chemotherapy.

Comparative in vitro activity of alexomycin (U-82127) tested against Escherichia coli, Salmonella spp., and enterococci of animal and human origin.

Ronald N. Jones, S. Marshall, Y. Chen, 1998, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Prevalence and Signiﬁcance of a Negative Extended-Spectrum (cid:2) -Lactamase (ESBL) Conﬁrmation Test Result after a Positive ESBL Screening Test Result for Isolates of Escherichia coli and Klebsiella pneumoniae : Results from the SENTRY Asia-Paciﬁc Surveillance Program (cid:1)

Ronald N. Jones, J. Turnidge, M. Barton, 2007 .

Evaluation of in vitro susceptibility testing criteria for gemifloxacin when tested against Haemophilus influenzae strains with reduced susceptibility to ciprofloxacin and ofloxacin.

Ronald N. Jones, D. Biedenbach, 2002, Diagnostic microbiology and infectious disease.

Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).

Ronald N. Jones, M. Pfaller, T. Fritsche, 2006, Diagnostic microbiology and infectious disease.

Pharmacokinetic and Pharmacodynamic Properties of Metronidazole in Pediatric Patients With Acute Appendicitis: A Prospective Study.

Ronald N. Jones, R. Mistry, Sarah K. Parker, 2019, Journal of the Pediatric Infectious Diseases Society.

MINIREVIEW Antimicrobial Susceptibility Testing of Haemophilus influenzae, Branhamella catarrhalis, and Neisseria gonorrhoeae

Ronald N. Jones, G. Doern, R. Jones, 2022 .

Resistance patterns among nosocomial pathogens: trends over the past few years.

Ronald N. Jones, R. Jones, 2001, Chest.

The North American Component (USA, Canada) of an International Comparative MIC Trial Monitoring Ofloxacin Resistance

Ronald N. Jones, D. Hoban, 1993, Drugs.

Reevaluation of contemporary laboratory methods for detection of antimicrobial resistance among enterococci.

Ronald N. Jones, M. Cormican, D. Biedenbach, 1996, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998

Ronald N. Jones, M. Pfaller, G. Doern, 2000, Antimicrobial Agents and Chemotherapy.

Prediction of Enterococcal Imipenem Susceptibility Using Ampicillin or Penicillin MICs: More Evidence for a Class Concept

Ronald N. Jones, 2001, Journal of Clinical Microbiology.

Evaluation of Interhospital Spread of Methicillin-Resistant Staphylococcus aureus in Sao Paulo, Brazil, Using Pulsed-Field Gel Electrophoresis of Chromosomal DNA

Ronald N. Jones, R. Hollis, H. Sader, 1994, Infection Control & Hospital Epidemiology.

Application of the Etest to the antimicrobial susceptibility testing of Mycobacterium marinum clinical isolates

Ronald N. Jones, C. M. Flynn, R. Jones, 1997, Journal of Clinical Microbiology.

Plasmid-borne vga(A)-encoding gene in methicillin-resistant Staphylococcus aureus ST398 recovered from swine and a swine farmer in the United States.

Ronald N. Jones, D. Diekema, H. Sader, 2011, Diagnostic microbiology and infectious disease.

Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial.

Ronald N. Jones, L. Turner, M. Castanheira, 2012, Diagnostic microbiology and infectious disease.

Agar Dilution and Disk Diffusion Susceptibility Testing of Campylobacter spp.

Ronald N. Jones, F. Aarestrup, L. Piddock, 2007 .

Antimicrobial susceptibility studies Characterization of fluoroquinolone-resistant h-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: Report from the SENTRY Antimicrobial Surve

Ronald N. Jones, M. Toleman, T. Walsh, 2006 .

Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999.

Ronald N. Jones, R. Ramphal, J. Turnidge, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans

Ronald N. Jones, M. Klepser, M. Pfaller, 1997, Antimicrobial agents and chemotherapy.

Important and emerging beta-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes.

Ronald N. Jones, R. Jones, 1998, Diagnostic microbiology and infectious disease.

Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE).

Ronald N. Jones, R. Wenzel, M. Edmond, 1997, Diagnostic microbiology and infectious disease.

Prevalence of important pathogens and the antimicrobial activity of parenteral drugs at numerous medical centers in the United States. II. Study of the intra- and interlaboratory dissemination of extended-spectrum beta-lactamase-producing Enterobacteriaceae.

Ronald N. Jones, M. Pfaller, R. Jones, 1994, Diagnostic microbiology and infectious disease.

The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada--1997 results from the SENTRY Antimicrobial Surveillance Program.

Ronald N. Jones, M. Pfaller, G. Doern, 1998, Diagnostic microbiology and infectious disease.

Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility.

Ronald N. Jones, R. Wenzel, M. Edmond, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-beta-lactamase in Spain: toward endemicity?

Ronald N. Jones, F. Baquero, R. Cantón, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014

Ronald N. Jones, M. Castanheira, H. Sader, 2016, Antimicrobial Agents and Chemotherapy.

Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Ronald N. Jones, L. Saiman, J. Burns, 2001, Diagnostic microbiology and infectious disease.

Ability of Latin America laboratories to detect antimicrobial resistance patterns: experience of the SENTRY Antimicrobial Surveillance Program (1997-2000).

Ronald N. Jones, A. Gales, H. Sader, 2003, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

In Vitro Activity and Single-Step Mutational Analysis of Rifamycin SV Tested against Enteropathogens Associated with Traveler’s Diarrhea and Clostridium difﬁcile (cid:1)

Ronald N. Jones, D. Farrell, G. Celasco, 2011 .

Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci.

Ronald N. Jones, R. Jones, L. Deshpande, 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia.

Ronald N. Jones, R. Jones, S. Bhavnani, 2000, Diagnostic microbiology and infectious disease.

Review of the in vitro spectrum of activity of imipenem.

Ronald N. Jones, R. Jones, Ronald N. Jones, 1985, The American journal of medicine.

Bacterial resistance: a worldwide problem.

Ronald N. Jones, M. Pfaller, R. Jones, 1998, Diagnostic microbiology and infectious disease.

Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program (1998).

Ronald N. Jones, R N Jones, W W Wilke, 2000, The Journal of antimicrobial chemotherapy.

Model of Infection Using a Dynamic In Vitro pneumoniae Streptococcus and Staphylococcus aureus Clindamycin Regimens against Evaluation of Low-Dose , Extended-Interval

Ronald N. Jones, M. Klepser, E. Ernst, 1999 .

Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I--results from the SENTRY Antimicrobial Surveillance Program (North America, 1998).

Ronald N. Jones, D. Mathai, M. Pfaller, 2001, Diagnostic microbiology and infectious disease.

Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997).

Ronald N. Jones, M. Pfaller, R. Jones, 2000, Diagnostic microbiology and infectious disease.

Reply: regional pooling of national data from a small number of sites can be misleading: maybe yes? But data can be complimentary to other studies and valuable to infectious disease physicians!

Ronald N. Jones, M. Castanheira, R. Mendes, 2014, Diagnostic microbiology and infectious disease.

Regional pooling of national data from a small number of sites can be misleading: maybe yes? But data can be complimentary to other studies and valuable to infectious disease physicians!

Ronald N. Jones, M. Castanheira, R. Mendes, 2014, Diagnostic microbiology and infectious disease.

MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections.

Ronald N. Jones, Jones, Pfaller, 2000, The Journal of antimicrobial chemotherapy.

Cefmetazole (CS-1170), a "new" cephamycin with a decade of clinical experience.

Ronald N. Jones, R. Jones, 1989, Diagnostic microbiology and infectious disease.

Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program.

Ronald N. Jones, M. Pfaller, R. Jones, 2001, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States.

Ronald N. Jones, R. Jones, D. Biedenbach, 2001, Diagnostic microbiology and infectious disease.

Clarithromycin, a unique macrolide. A pharmacokinetic, microbiological, and clinical overview.

Ronald N. Jones, D. Guay, R. Jones, 1992, Diagnostic microbiology and infectious disease.

Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012-2014.

Ronald N. Jones, M. Castanheira, M. Huband, 2016, Surgical infections.

In Vitro Activity of RX-P873 against Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii

Ronald N. Jones, P. Rhomberg, D. Farrell, 2015, Antimicrobial Agents and Chemotherapy.

Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997.

Ronald N. Jones, M. Pfaller, R. Jones, 1999, Diagnostic microbiology and infectious disease.

Ronald N. Jones, M. Castanheira, M. Pfaller, 2011, International journal of antimicrobial agents.

Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012).

Ronald N. Jones, D. Farrell, H. Sader, 2014, International journal of antimicrobial agents.

Daptomycin Activity against Uncommonly Isolated Streptococcal and Other Gram-Positive Species Groups

Ronald N. Jones, D. Farrell, H. Sader, 2013, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative Staphylococcus.

Ronald N. Jones, H. Sader, 2012, Diagnostic microbiology and infectious disease.

Activity of daptomycin against gram-positive bacterial isolates from Indian medical centres (2006-2007).

Ronald N. Jones, J. Turnidge, D. Mathai, 2009, International journal of antimicrobial agents.

Ronald N. Jones, M. Castanheira, M. Pfaller, 2011, Diagnostic microbiology and infectious disease.

Ronald N. Jones, M. Castanheira, M. Pfaller, 2010, Journal of Clinical Microbiology.

Ronald N. Jones, P. Rhomberg, D. Farrell, 2015, Journal of Clinical Microbiology.

Binaphthyl-based dicationic peptoids with therapeutic potential.

Ronald N. Jones, Michael H. Miller, J. Deadman, 2010, Angewandte Chemie.

First Report of cfr-Mediated Resistance to Linezolid in Human Staphylococcal Clinical Isolates Recovered in the United States

Ronald N. Jones, M. Castanheira, R. Mendes, 2008, Antimicrobial Agents and Chemotherapy.

Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia.

Ronald N. Jones, R. Jones, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Nosocomial streptococcal blood stream infections in the SCOPE Program: species occurrence and antimicrobial resistance. The SCOPE Hospital Study Group.

Ronald N. Jones, R. Wenzel, M. Edmond, 1997, Diagnostic microbiology and infectious disease.

Broth Microdilution Susceptibility Testing of Campylobacter jejuni and the Determination of Quality Control Ranges for Fourteen Antimicrobial Agents

Ronald N. Jones, P. McDermott, T. Fritsche, 2006, Journal of Clinical Microbiology.

Phenotypic detection of mec A-positive staphylococcal blood stream isolates: high accuracy of simple disk diffusion tests.

Ronald N. Jones, M. Cormican, M. Pfaller, 1996, Diagnostic microbiology and infectious disease.

Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999.

Ronald N. Jones, D. Low, R. Jones, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Microbiological Assessment of Polymyxin B Components Tested Alone and in Combination

Ronald N. Jones, J. Rotschafer, P. Rhomberg, 2015, Antimicrobial Agents and Chemotherapy.

Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).

Ronald N. Jones, M. Pfaller, R. Jones, 2001, Diagnostic microbiology and infectious disease.

Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011).

Ronald N. Jones, D. Farrell, H. Sader, 2014, Diagnostic microbiology and infectious disease.

Evaluation of Daptomycin Activity Tested against 34,603 Bacterial Strains from Hospitalized Patients: Summary of a 4 Year Surveillance Program for North America and Europe (2002-2005)

Ronald N. Jones, 2006 .

Antimicrobial susceptibility testing of Haemophilus influenzae, Branhamella catarrhalis, and Neisseria gonorrhoeae

Ronald N. Jones, G. Doern, 1988, Antimicrobial Agents and Chemotherapy.

Update on Fusidic Acid (CEM-102) Tested against Neisseria gonorrhoeae and Chlamydia trachomatis

Ronald N. Jones, S. Kohlhoff, M. Hammerschlag, 2010, Antimicrobial Agents and Chemotherapy.

Practical approach to the identification of clinically relevant Enterococcus species.

Ronald N. Jones, D. Low, B. Willey, 1999, Diagnostic microbiology and infectious disease.

Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal disease.

Ronald N. Jones, P. Rhomberg, D. Farrell, 2014, Diagnostic microbiology and infectious disease.

Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study.

Ronald N. Jones, H. Sader, R. Mendes, 2010, The Journal of antimicrobial chemotherapy.

Increased antimicrobial susceptibility profiles among polymyxin-resistant Acinetobacter baumannii clinical isolates.

Ronald N. Jones, T. Fritsche, H. Sader, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998.

Ronald N. Jones, R. Ramphal, M. Pfaller, 2000, International journal of antimicrobial agents.

Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options.

Ronald N. Jones, M. Castanheira, R. Mendes, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Reevaluation of Clinical and Laboratory Standards Institute Disk Diffusion Breakpoints for Tetracyclines for Testing Enterobacteriaceae

Ronald N. Jones, M. Ferraro, L. Reller, 2007, Journal of Clinical Microbiology.

Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008).

Ronald N. Jones, P. Rhomberg, 2009, Diagnostic microbiology and infectious disease.

Multicenter Evaluation of Tigecycline: An in Vitro Update Against Clinical Pathogens from Japan (2006–2007)

Ronald N. Jones, M. Castanheira, K. Yanagihara, 2008 .

Identification and Antimicrobial Susceptibility Testing of Branhamella catarrhalis in United States Laboratories, 1983–1985

Ronald N. Jones, H. Sommers, 2012, Drugs.

Results from the Solithromycin International Surveillance Program (2014)

Ronald N. Jones, D. Farrell, H. Sader, 2016, Antimicrobial Agents and Chemotherapy.

Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination

Ronald N. Jones, R. Jones, A. Barry, 1988, Journal of clinical microbiology.

Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis.

Ronald N. Jones, M. Piedmonte, J. Anon, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Organisms Collected from U.S. Medical Centers in 2012

Ronald N. Jones, M. Castanheira, D. Farrell, 2013, Antimicrobial Agents and Chemotherapy.

In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers.

Ronald N. Jones, P. Murray, R. Jones, 1993, Diagnostic microbiology and infectious disease.

Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method.

Ronald N. Jones, D. Farrell, H. Sader, 2015, Diagnostic microbiology and infectious disease.

Reanalysis of cefazolin surrogate susceptibility breakpoints utilized as guidances for oral cephalosporin treatments of uncomplicated urinary tract infections: caution concerning application to cefadroxil.

Ronald N. Jones, Hien M. Nguyen, 2020, Diagnostic microbiology and infectious disease.

Oxazolidinone antibiotics

Ronald N. Jones, D. Diekema, 2001, The Lancet.

Occurrence of macrolide-lincosamide-streptogramin resistances among staphylococcal clinical isolates at a university medical center. Is false susceptibility to new macrolides and clindamycin a contemporary clinical and in vitro testing problem?

Ronald N. Jones, Martha L. Sanchez, R. Jones, 1993, Diagnostic microbiology and infectious disease.

Antimicrobial activity of gatifloxacin (AM-1155, CG5501), and four other fluoroquinolones tested against 2,284 recent clinical strains of Streptococcus pneumoniae from Europe, Latin America, Canada, and the United States. The SENTRY Antimicrobial Surveillance Group (Americas and Europe).

Ronald N. Jones, J. Verhoef, R. Jones, 1999, Diagnostic microbiology and infectious disease.

Summary of Linezolid Activity and Resistance Mechanisms Detected during the 2012 LEADER Surveillance Program for the United States

Ronald N. Jones, R. Mendes, R. Flamm, 2013, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014

Ronald N. Jones, M. Castanheira, M. Huband, 2016, Antimicrobial Agents and Chemotherapy.

Comparative in Vitro Activity of Zabofloxacin (DW-224a) Tested Against Multidrug-Resistant Neisseria gonorrhoeae

Ronald N. Jones, T. Fritsche, P. Ambrose, 2008 .

The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci.

Ronald N. Jones, R. Jones, D. Biedenbach, 1996, Diagnostic microbiology and infectious disease.

Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains.

Ronald N. Jones, P. Ambrose, D. Biedenbach, 2008, Diagnostic microbiology and infectious disease.